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Abstract 
 
XI 
 
Histone deacetylase (HDAC) inhibitors are protective in several models of 
neurodegenerative diseases. Specifically, HDAC inhibition enhanced mitochondrial Ca2+ 
handling in Huntington’s disease (HD) cell models – which may prove beneficial for striatal 
neurons, given their sensitivity to Ca2+-loads. HD is associated with mitochondrial 
dysfunction, mitochondrial fragmentation and trafficking impairment. Pharmacological 
modulation of mitochondrial dynamics is considered a promising strategy to counteract 
mitochondrial dysfunction and modify HD progression. Inhibition of the -tubulin 
deacetylase HDAC6 is known to increase mitochondrial trafficking, but whether inhibiting 
HDACs in neurons modulates mitochondrial biogenesis or fission-fusion balance remains 
to be addressed. Additionally, increasing -tubulin acetylation by inhibiting HDAC6 may 
also promote transport of autophagic vesicles and consequently elevate neuronal 
autophagic flux. However, given that HDAC6 activity is reportedly required for 
autophagosome-lysosome fusion in cell-lines, the impact of HDAC6 inhibition for the 
autophagic pathway in neurons is unclear. In this thesis, we assessed the effects of HDAC1 
inhibitor MS-275, and HDAC6 inhibitor tubastatin, on mitochondrial dynamics in cortical and 
striatal neurons. We also tested whether HDAC6 inhibition blocks autophagy and mutant 
huntingtin (mHtt) clearance in neurons. Our results show that neither HDAC1 nor HDAC6 
inhibition altered mitochondrial biogenesis. HDAC6 inhibition increased -tubulin 
acetylation, which promoted mitochondrial motility and fusion in HD-vulnerable striatal 
neurons – a promising finding, since striatal mitochondria were smaller and less motile than 
mitochondria in the less HD-vulnerable cortical neurons. HDAC6 inhibition did not block 
neuronal autophagosome-lysosome fusion or mHtt clearance but instead, increased LC3-
vesicle retrograde flux and reduced diffuse mHtt levels in striatal neurons. Results from this 
thesis suggest that HDAC6 inhibition may be a promising pharmacological strategy to 
reduce striatal neurons vulnerability in HD. 
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Resumo 
 
XV 
 
Os inibidores das desacetilases de histonas (HDACs) são protetores em vários modelos 
de doenças neurodegenerativas. Especificamente, a inibição das HDACs melhorou o 
controlo mitocôndrial de Ca2+ em modelos celulares da doença de Huntington (DH) – o que 
poderá ser benéfico para os neurónios estriatais, devido à sua sensibilidade a cargas de 
Ca2+. A DH está associada a disfunção mitocôndrial, fragmentação e distúrbios no tráfego 
mitocôndrial. A modulação farmacológica da dinâmica mitocôndrial é considerada uma 
estratégia promissora para contrariar a disfunção mitocôndrial e modificar a progressão da 
DH. Sabe-se que a inibição da -tubulina desacetilase HDAC6 aumenta o tráfego 
mitocôndrial, mas continua por ser testado em neurónios se a biogénese mitocôndrial ou o 
equilíbrio fissão-fusão são modulados pela inibição das HDACs. Adicionalmente, o 
aumento da acetilação da -tubulina através da inibição da HDAC6 poderá também 
promover o transporte das vesículas autofágicas e consequentemente elevar o fluxo 
autofágico neuronal. No entanto, visto que se encontra documentado que a atividade da 
HDAC6 é necessária para a fusão autofagossoma-lisossoma em linhas-celulares, o 
impacto da inibição da HDAC6 para a via autofágica em neurónios não é claro. Nesta tese, 
abordámos os efeitos do inibidor da HDAC1 MS-275, e do inibidor da HDAC6 tubastatina, 
sobre a dinâmica mitocôndrial em neurónios corticais e estriatais. Testámos também se a 
inibição da HDAC6 bloqueia a autofagia e a degradação de huntingtina mutante (mHtt) em 
neurónios. Os nossos resultados mostram que nem a inibição da HDAC1 ou da HDAC6 
alteraram a biogénese mitocôndrial. A inibição da HDAC6 levou a um aumento da 
acetilação da -tubulina, o que estimulou a motilidade e fusão mitocôndrial em neurónios 
estriatais sensíveis à DH – um resultado promissor, uma vez que as mitocôndrias estriatais 
eram mais pequenas e menos móveis que as mitocôndrias em neurónios corticais, menos 
sensíveis à DH. A inibição da HDAC6 não bloqueou a fusão autofagossoma-lisossoma ou 
a degradação da mHtt mas, ao invés disso, aumentou o fluxo retrógrado das vesículas 
LC3-positivas e reduziu os níveis de mHtt difusa em neurónios estriatais. Os resultados 
desta tese sugerem que a inibição da HDAC6 poderá ser uma estratégia farmacológica 
promissora para reduzir a vulnerabilidade dos neurónios estriatais na DH. 
 
Palavras-chave: HDACs, mitocôndria, autofagia, neurónios, huntingtina
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Thesis outline 
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This thesis is divided in four main sections: 
 
Section 1 – Background and hypotheses 
 
Brief literature review to contextualize this thesis research objectives. 
 
Section 2 – Research 
 
The two articles developed within the scope of this thesis. 
1 – (Review article) Guedes-Dias, P. and Oliveira, J.M. (2013) Lysine deacetylases and 
mitochondrial dynamics in neurodegeneration. Biochimica et Biophysica Acta – Molecular 
Basis of Disease 1832(8):1345-59 
2 – (Original research article) Guedes-Dias, P., de Proença, J., Soares, T.R., Leitão-Rocha, 
A., Duchen, M.R., Oliveira, J.M. (2015) Submitted 
 
Section 3 – Discussion and future directions 
 
Discussion of this thesis experimental findings, highlighting open questions for future 
investigation. 
 
Section 4 – References 
List of studies cited in Section 1 and Section 3. 
Studies cited in Section 2 are listed at the end of the respective article. 
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HISTONE DEACETYLASES (HDACs) 
Acetylation is a post-translational modification regulated by the opposing activity of 
histone acetyltransferases (HATs) and histone deacetylases (HDACs). Histone acetylation 
was first described in 1964 (Allfrey et al., 1964; Murray, 1964) and histone deacetylase 
activity a few years later (Inoue and Fujimoto, 1969, 1970). Currently, over 1750 proteins 
distributed across the nucleus, cytoplasm and mitochondria are known to be acetylated in 
human cells (Choudhary et al., 2009). In mammals, the deacetylation of such diverse range 
of proteins is carried out by 18 HDAC isoforms. These may be either divided in two groups, 
based on yeast HDAC homology (‘classical HDACs’ – Zn2+-dependent, and ‘sirtuins’ – 
NAD+-dependent), or four classes, based on phylogenetic analysis and sequence homology 
(‘classical HDACs’ comprise class I, class IIa/IIb and IV; ‘sirtuins’ are included in class III) 
(Yang and Seto, 2008). 
HDAC1 is a class I isoform that is ubiquitously expressed across tissues. Typically, 
HDAC1 resides in the nucleus and is found associated with HDAC2 in co-repressor 
complexes that associate with DNA and regulate gene transcription (Sengupta and Seto, 
2004). Although initially the predominant model was that histone deacetylation induced 
states of transcriptional repression, the current understanding is that there is an interplay 
between different epigenetic mechanisms which render transcription regulation rather more 
complex and difficult to predict (Falkenberg and Johnstone, 2014). Studies in yeast and 
mammalian cells revealed that HDAC1/2 knockouts were associated with the down-
regulation of a significant portion of genes, indeed suggesting that HDAC1/2 activity are 
involved in the activation of some genes (Kelly and Cowley, 2013). Additionally, HDAC1 
pharmacological inhibition was reported to reduce expression levels of fission protein Fis1 
in cell-lines (Lee et al., 2012).  
Constitutive HDAC1 knockout mice are embryonically lethal (E10.5; Lagger et al., 
2002). In neurons, HDAC1 is reportedly involved in DNA damage repair (Dobbin et al., 2013; 
Wang et al., 2013) and synaptogenesis (Akhtar et al., 2009; Yamada et al., 2014), but 
conditional HDAC1 deletion neither alters neuronal development (Montgomery et al., 2009) 
nor learning and memory performances (Morris et al., 2013). Some studies have implicated 
HDAC1 activity as a contributing factor for neurodegeneration. In a Huntington’s disease 
(HD) mouse model, HDAC1 was reported to be upregulated in the striatum, a particularly 
vulnerable brain region in HD (Bardai et al., 2012), whereas in a neuroinflammation model, 
HDAC1 was detected to impair mitochondrial trafficking by shuttling to the cytosol and 
reducing -tubulin acetylation (Kim et al., 2010). 
Background and hypotheses 
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HDAC6 is a class IIb isoform, highly expressed in neurons and primarily localized in 
the cytoplasm (Southwood et al., 2007). In humans, the HDAC6 cytoplasmic localization is 
achieved by two nuclear export signals (NES1 and 2) and maintained by a cytoplasmic 
retention Ser-Glu-containing tetradecapeptide (SE14) domain (Bertos et al., 2004). Murine 
HDAC6 do not present a SE14 motif and albeit containing NES1, the region corresponding 
to NES2 is less conserved and reported to be nonfunctional (Verdel et al., 2000; Bertos et 
al., 2004). The C-terminal zinc finger motif (ZnF-UBP) in HDAC6 is a unique feature among 
the HDAC superfamily (Simões-Pires et al., 2013) and allows binding to free ubiquitin and 
both mono- and polyubiquitinated proteins (Li et al., 2013). A dynein motor binding (DMB) 
domain is thought to assist the microtubule-based retrograde transport of ubiquitinated 
proteins to the perinuclear region via HDAC6 (Kawaguchi et al., 2003). Unlike other known 
members of the HDAC superfamily, HDAC6 possesses two active deacetylase domains, 
DD1 and DD2 (Simões-Pires et al., 2013). The relative contribution of each deacetylase 
domain to the overall HDAC6 activity remains unclear, but is possibly substrate-dependent 
(Li et al., 2011; Li et al., 2013). HDAC6 deacetylates a number of non-histones proteins, 
including -tubulin, cortactin and Hsp90, and is thus involved in the regulation of 
microtubule-based transport, cell motility and chaperone activity (Guedes-Dias and Oliveira, 
2013).  
 
 
 
Figure 1. Schematic representation and functional domains of human HDAC6. Original 
image from Li et al., (2013) FEBS Letters. 
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Several neurodegenerative diseases are associated with intracellular transport 
defects (Sheng and Cai, 2012; Maday et al., 2014). In particular, brains of HD patients show 
reduced levels of acetylated -tubulin and neurons expressing mutant huntingtin present 
impaired axonal transport (Dompierre et al., 2007). Acetylated -tubulin promotes 
recruitment of motor proteins to microtubules and microtubule-mediated transport (Reed et 
al., 2006; Dompierre et al., 2007). Inhibiting the -tubulin deacetylase HDAC6 is, therefore, 
considered a promising approach to rescue transport defects in neurodegeneration. Indeed, 
HDAC6 activity inhibition has been shown to improve neuronal mitochondrial trafficking in 
vitro (Chen et al., 2010; d'Ydewalle et al., 2011) and showed beneficial effects in in vivo 
models of Alzheimer’s disease (Govindarajan et al., 2013), amyotrophic lateral sclerosis 
(Taes et al., 2013) and Charcot-Marie-Tooth disease (d'Ydewalle et al., 2011). 
HDAC inhibitors are generally divided in three structural components: the metal-
binding moiety, which coordinates the catalytic Zn2+ ion within the active site; the capping 
group moiety, which interacts with aminoacid residues surrounding the entrance of the 
active site; and the linker region, which connects the two (Bieliauskas and Pflum, 2008). 
Selective pharmacological inhibition among class I, II and IV HDAC isoforms has been 
difficult to achieve due to high catalytic domain homology (Bieliauskas and Pflum, 2008). 
First generation HDAC inhibitors, such as trichostatin A (TSA) and vorinostat (SAHA), do 
not show isoform or class selectivity and are usually referred to as broad spectrum or pan-
HDAC inhibitors. In recent years, however, greater understanding of the structural biology 
and molecular modeling of HDACs has led to the design and synthesis of small molecules 
with significantly improved selectivity profiles (Thaler and Mercurio, 2014). Examples of 
such molecules are the two inhibitors used in this thesis: MS-275 and tubastatin A, which 
preferentially inhibit HDAC1 and HDAC6, respectively (Figure 2).  
Background and hypotheses 
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Figure 2. The two HDAC inhibitors used in this study: (A) MS-275, also known as entinostat, 
is considered a class I inhibitor with preferential selectivity towards HDAC1 (IC50 181 nM 
and >6-fold selectivity over HDAC2; Khan et al., 2008; Bradner et al., 2010); (B) Tubastatin 
A (TBA), is a selective HDAC6 inhibitor (IC50 15 nM and >50-fold selectivity over HDAC8; 
Butler et al., 2010).
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HUNTINGTON’S DISEASE 
Huntington’s disease (HD) is a monogenic and dominantly inherited 
neurodegenerative disease characterized by motor dysfunction, cognitive decline and 
psychiatric disturbances (Ross and Tabrizi, 2011). HD is caused by an expansion of the 
CAG trinucleotide repeat in the gene encoding the protein huntingtin (Htt) (The Huntington’s 
Disease Collaborative Research Group, 1993). Expansions containing between 36 and 40 
CAG-encoded glutamines have incomplete penetrance, whereas expansions of 41 or more 
glutamines are fully penetrant (Walker, 2007). Mutant Htt (mHtt) is expressed during the 
individual whole lifetime, but disease onset is typically around 40 years. Significantly, 
despite widespread distribution of mHtt, preferential atrophy of the striatum is observed 
even prior to HD onset (Paulsen et al., 2010; Aylward et al., 2011) – consequence of 
substantial degeneration of GABAergic medium spiny neurons (MSNs; Ross and Tabrizi, 
2011). Why are the striatal MSNs particularly vulnerable to mHtt is an outstanding question 
in the field and significant efforts to unveil specific cellular and molecular mechanisms that 
might contribute for such vulnerability continue to be made. 
Several factors including mitochondrial dysfunction (Johri et al., 2013) and altered 
proteostasis pathways (Margulis and Finkbeiner, 2014) are thought to be involved in HD 
pathology. Importantly, they have been implicated as likely factors that render striatal 
neurons preferential vulnerability in HD: both mitochondria isolated from the striatum 
(Brustovetsky et al., 2003) and mitochondria in cultured striatal neurons (Oliveira and 
Gonçalves, 2009) are more vulnerable to Ca2+-loads than their cortical counterparts; diffuse 
mHtt disrupts mitochondrial trafficking in striatal (Orr et al., 2008) but not cortical neurons 
(Chang et al., 2006), and diffuse mHtt is less efficiently cleared in striatal compared to 
cortical or cerebellar neurons (Tsvetkov et al., 2013). Thus, strategies to prevent 
mitochondrial dysfunction and to improve mHtt clearance are considered potentially useful 
in HD (Costa and Scorrano, 2012; Nixon, 2013). Given the role of protein acetylation in 
autophagy (True and Matthias, 2012; Bánréti et al., 2013) and mitochondrial dynamics 
(Schon and Przedborski, 2011; Guedes-Dias and Oliveira, 2013), we were interested in 
evaluating HDAC inhibition as a potential modifier of striatal neurons vulnerability in HD. 
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MITOCHONDRIAL BIOGENESIS 
The mammalian mitochondrial proteome is estimated to comprise between 1100 
and 1500 proteins, of which 13 are encoded by the mitochondrial DNA and the remainder 
by the nuclear DNA (Meisinger et al., 2008; Pagliarini et al., 2008). Since mitochondria 
cannot be generated de novo, pre-existing mitochondria are used as templates to generate 
more mitochondrial mass in a process involving a tight orchestration between the nuclear, 
cytosolic and mitochondrial compartments. In the nucleus, expression of genes encoding 
for mitochondrial proteins is regulated by a family of transcription coactivators, of which 
PGC-1 is considered the main member, and further coordinated by a group of transcription 
factors, which include the nuclear respiratory factor 1 (NRF1) and 2 (NRF2; Scarpulla, 
2011). Following translation in the cytosol, proteins are imported into mitochondria and 
targeted to specific mitochondrial subcompartments, where they may be further assembled 
into functional complexes (DiMauro et al., 2013). Coordination of mitochondrial biogenesis 
is established by a circuit which integrates external and internal signals into genetic 
programs (Battersby and Richter, 2013). Specifically, cellular growth and physiological 
states, such as long-term cold exposure, nutrient deprivation and exercise, alter the energy 
demands of particular cells or tissues and activate signaling pathways that regulate gene 
transcription and mitochondrial biogenesis (Scarpulla et al., 2012). Indeed, several studies 
have addressed strategies to modulate those signaling pathways and rescue levels of 
mitochondrial biogenesis in neurodegenerative diseases (Schapira et al., 2014; Corona and 
Duchen, 2015).  
In developing neurons, mitochondria are distributed from the cell body to emerging 
axons (Ruthel and Hollenbeck, 2003) and concentrate in active growth cones, where ATP 
consumption is elevated (Morris and Hollenbeck, 1993; Ruthel and Hollenbeck, 2003). 
Mitochondrial energy production is essential for neurite outgrowth and morphogenesis both 
in vitro and in vivo (Oruganty-Das et al., 2012) thus, significant levels of mitochondrial 
biogenesis support neurite extension. Moreover, in mice dentate gyrus, considerable 
mitochondrial biogenesis takes place in adult-born granule neurons even beyond the period 
of maximal dendritic arbor extension, underscoring the reliance of mature neurons on 
mitochondrial metabolism (Steib et al., 2014). The paradigm of neurite extension during 
neuronal maturation led some authors to favor a model in which mitochondrial biogenesis 
occurs mainly in the cell body (O'Toole et al., 2008). Interestingly, however, detection of 
axonal mRNA for nuclear-encoded mitochondrial proteins (Gioio et al., 2001) was followed 
by the observation of mitochondrial biogenesis occurring in axons separated from their cell 
bodies (Amiri and Hollenbeck, 2008). 
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HDAC class III isoform SIRT1 is reported to deacetylate and activate PGC-1, 
increasing mitochondrial biogenesis (Canto and Auwerx, 2009). Both HDAC6 and HDAC1 
inhibition have been reported to promote neurite extension in cortical (Rivieccio et al., 2009) 
and dorsal root ganglion neurons (Finelli et al., 2013), respectively. However, whether 
HDAC1 and HDAC6 inhibition modify neuronal mitochondrial biogenesis levels remains 
unknown. In this thesis, we thus assessed whether altered neurite outgrowth caused by 
HDAC1 and HDAC6 inhibition could be associated with changes on mitochondrial 
biogenesis levels in developing cortical and striatal neurons. 
Background and hypotheses 
 
13 
 
MITOCHONDRIAL TRANSPORT 
A single cortical neuron in the resting brain is estimated to consume about 4.7 billion 
ATP molecules per second (Zhu et al., 2012). A large part of this energy is produced in 
mitochondria and is used far away from the cell body in synapses and conducting action 
potentials (Schwarz, 2013). Proper mitochondrial distribution throughout the neuritic arbor 
is thus essential for neuronal function and it is achieved by a highly complex and specialized 
intracellular transport system. 
Mitochondrial transport in neurons is mainly mediated along microtubules by two 
superfamilies of opposing motors: kinesins and dyneins. Whereas kinesins process cargo 
transport towards the plus end of microtubules (anterograde), minus end-directed 
(retrograde) cargo transport is regulated by dyneins. The kinesin-1 family is the main 
mediator of mitochondrial anterograde transport and, in mammals, attaches to mitochondria 
through the Miro/TRAK1-2 adaptor complex (MacAskill et al., 2009a). Ca2+ binds to EF-
hand domains in Miro, altering its conformation and arresting kinesin-1 processing – a 
mechanism thought to underlie mitochondrial immobilization in areas of locally high Ca2+ 
concentration (Macaskill et al., 2009b; Wang and Schwarz, 2009). Other protein adaptors 
that assist kinesin-1 recruitment to mitochondria include FEZ1, RanBP2 and syntabulin 
(Maday et al., 2014). Dynein requires binding to dynactin to process minus-end directed 
cargo transport (Moughamian and Holzbaur, 2012). Evidence suggest that the dynein-
dynactin motor complex also attaches to mitochondria through the Miro/TRAKs complex: 
dynein-dynactin was found to interact with TRAK proteins (van Spronsen et al., 2013) and 
loss of Miro in Drosophila affects mitochondrial movement in both anterograde and 
retrograde directions (Russo et al., 2009). Mechanisms to immobilize mitochondria in sites 
of high Ca2+ concentration and energy consumption are fundamental to assure proper 
mitochondrial distribution (Sheng, 2014). One important mediator for mitochondrial docking 
in axons is syntaphilin, which immobilizes mitochondria by anchoring them to microtubules 
(Chen and Sheng, 2013). Interestingly, the absence of syntaphilin in dendrites (Kang et al., 
2008) and the different mitochondrial-arrest mechanisms mediated by Miro/Ca2+ in axons 
(Wang and Schwarz, 2009) and dendrites (Macaskill et al., 2009b), suggest that 
mitochondrial docking is differentially regulated in distinct neuronal regions. 
Mitochondrial transport defects have been implicated in a number of 
neurodegenerative diseases and particularly in HD (Sheng and Cai, 2012). Diffuse mutant 
huntingtin impaired mitochondrial trafficking in striatal neurons (Orr et al., 2008), whereas 
in cortical neurons, mitochondria tended to stop and accumulate only next to aggregates 
(Chang et al., 2006). This suggests that mutant huntingtin preferentially affects 
mitochondrial transport in striatal neurons and that this factor might be an important
Background and hypotheses 
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contributor for striatal neurons vulnerability in HD. Why is there a more striking inhibition of 
mitochondrial trafficking in striatal than in cortical neurons is unclear. To address this issue, 
we used sister cultures of cortical and striatal neurons to analyze whether basal 
mitochondrial trafficking parameters differed between the two neuronal populations. 
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MITOCHONDRIAL FISSION-FUSION 
Mitochondrial fission and fusion events are mainly mediated by a group of conserved 
GTPases and permit the modulation of mitochondrial morphology, number and size. 
Mitochondrial fission allows for the isolation of defective mitochondria, the partition of 
mitochondria to daughter cells during mitosis, and the distribution of mitochondria along 
neuronal processes (Otera and Mihara, 2011). The cytosolic dynamin-related protein 1 
(Drp1) is the main mediator of mitochondrial fission, forming spirals around mitochondria 
which constrict and ultimately split both outer and inner mitochondrial membranes 
(Smirnova et al., 2001). In mammals, recruitment and assembly of Drp1 on the 
mitochondrial outer membrane are mediated by a group of effector proteins, which include 
Fis1, Mff, MiD49 and MiD51 (DuBoff et al., 2013). Mitochondrial fusion is thought to render 
functional complementation between mitochondria by allowing the distribution of mtDNA, 
RNA, proteins and lipids among them (Youle and van der Bliek, 2012). In mammals, 
membrane-anchored Mitofusin 1 (Mfn1) and 2 (Mfn2) mediate the fusion of mitochondrial 
outer membranes, while Optic Atrophy 1 (OPA1) mediates the fusion of mitochondrial inner 
membranes (Chan, 2006). At a mechanistic level, it is thought that fusion-GTPases 
anchored on two opposing membranes form homo- or hetero-complexes that allow 
mitochondrial tethering and consequent fusion (Chan, 2006). 
Neurons are particularly sensitive to defective mitochondrial fission-fusion balance. 
Mutations in OPA1 cause autosomal dominant optic atrophy, which is characterized by 
retinal ganglion cell degeneration and visual loss, while mutations in Mfn2 cause Charcot-
Marie-Tooth disease type 2A neuropathy (Itoh et al., 2013). Mounting evidence suggest that 
altered mitochondrial fission-fusion balance is also a pathophysiological trait in other 
neurodegenerative diseases (DuBoff et al., 2013; Itoh et al., 2013). HD, in particular, has 
been associated with increased mitochondrial fragmentation: Drp1 and Fis1 expression 
levels were reported to be increased in brains of HD patients (Shirendeb et al., 2011), and 
additionally, mutant huntingtin was described to interact and increase Drp1 enzymatic 
activity (Song et al., 2011; Shirendeb et al., 2012). Concomitantly, there has been a growing 
interest in researching strategies to correct mitochondrial structural defects in HD (Costa 
and Scorrano, 2012). A recent study reported that pharmacological inhibition of Drp1 
prevented excessive mitochondrial fragmentation and improved survival of both in vitro and 
in vivo HD models (Guo et al., 2013). Even so, evidence indicating that inhibition of 
mitochondrial fission is not beneficial for neurons in the long-term (Li et al., 2004; Kageyama 
et al., 2012; Sheng and Cai, 2012), suggests that strategies aiming at promoting 
mitochondrial fusion might be more promising for HD. 
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Neuronal mitochondria frequently go through fission and fusion cycles (Cagalinec et 
al., 2013). The number of contacts between mitochondria predicts fusion events in neurons 
and is mostly dependent on two factors: 1) the number of mitochondria available and 2) 
mitochondrial movement (Cagalinec et al., 2013). Modulation of one of these factors is 
therefore likely to alter mitochondrial fission-fusion balance. HDAC6 inhibition increases -
tubulin acetylation, which in turn promotes motor proteins recruitment to microtubules (Reed 
et al., 2006; Dompierre et al., 2007) and mitochondrial motility in neurons (Chen et al., 2010; 
d'Ydewalle et al., 2011). We thus hypothesized that enhancing mitochondrial motility by 
inhibiting HDAC6 would increase the number of contacts between mitochondria and 
facilitate mitochondrial fusion. This hypothesis was particularly appealing since HD is not 
only associated with mitochondrial fragmentation, but also with decreased levels of -
tubulin acetylation (Dompierre et al., 2007) and defective mitochondrial transport (Chang et 
al., 2006; Orr et al., 2008) – which could be potentially rescued by inhibiting HDAC6.
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AUTOPHAGIC DYNAMICS 
Autophagy and the ubiquitin-proteasome system (UPS) are the two main 
mechanisms in the cell for disposing toxic and defective components. The importance of 
autophagy as a mechanism which confers efficient degradation of defective organelles and 
misfolded protein aggregates is most evident in neurons (Nixon, 2013). Whereas cell-lines 
may divide to segregate and dilute toxic components (Eden et al., 2011), such mechanisms 
are precluded from post-mitotic and long-lived neurons. Moreover, neurons are highly 
polarized, which further compels a unique degree of autophagy spatial regulation. Indeed, 
neuron-specific knockdown of essential components of the autophagic pathway resulted in 
severe neurodegenerative phenotypes (Hara et al., 2006; Komatsu et al., 2006) and 
mounting evidence suggest that autophagy defects are associated with several 
neurodegenerative diseases, including HD (Martin et al., 2015).  
The autophagic machinery has been largely identified through yeast genetic studies 
(Reggiori and Klionsky, 2013) and it consists of approximately 35 autophagy-related 
proteins (Atg) which mostly function as multiprotein complexes (Mizushima and Komatsu, 
2011). In mammalian cells, core Atg proteins are highly conserved and act in a similar 
hierarchical manner as in yeast (Mizushima and Komatsu, 2011). The autophagic pathway 
involves the formation of an isolation membrane (or phagophore) which nucleates from the 
endoplasmic reticulum (other cellular compartments, such as the Golgi complex, 
mitochondria and plasma membrane, are thought to contribute for the isolation membrane 
expansion; Lamb et al., 2013). The isolation membrane grows, engulfing a portion of the 
cytoplasm and eventually taking a fishbowl-like shape (Hurley and Schulman, 2014). When 
the isolation membrane is sealed and detaches from the endoplasmic reticulum, the newly 
formed vesicle is referred to as the autophagosome – this structure ultimately fuses with a 
lysosome, resulting in the degradation of its contents (Hurley and Schulman, 2014). 
Significantly, this pathway has been extensively studied in yeast and mammalian cell-lines, 
however, only in recent years has the neuronal autophagic pathway been addressed in 
further detail.
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Figure 3. Original image and legend from Mizushima and Komatsu (2011) Cell. 
 
In neurons, the autophagic pathway is highly compartmentalized – over 80% of 
autophagosomes generate at the axon tip (Maday and Holzbaur, 2014) and are retrogradely 
transported along the axon towards the somatodendritic compartment, where most of the 
cargo degradation is thought to take place (Lee et al., 2011; Maday et al., 2012). Similarly 
to nonpolarized cells, Atg13 recruitment to nascent autophagosomes occurs prior to double 
FYVE-containing protein 1 (DFCP1) and LC3 recruitment (Maday and Holzbaur, 2014). 
Although studies have positioned Atg5 downstream of Atg13 and DFCP1 (Itakura and 
Mizushima, 2010), Atg5 recruitment was unexpectedly observed to occur simultaneously 
with Atg13, which could have been due to the relatively low time resolution used in the 
reported experimental context (2 sec; Maday and Holzbaur, 2014)). The disassembly of 
proteins at the nucleation site also takes place in an orderly fashion, with Atg5 exit being 
followed by loss of Atg13 and ultimately, DFCP1 decay (Maday and Holzbaur, 2014). 
Autophagosomal biogenesis is followed by the highly processive retrograde transport of 
autophagosomes towards the somatodendritic region. The motor proteins kinesin and 
dynein bind to autophagosomes in the axonal tip, leading to a tug-of-war between the two 
motors in which autophagosomes are observed moving bidirectionally with frequent 
direction switching (Fu et al., 2014). The tug-of-war is resolved when JIP1 is recruited to 
autophagosomes and binds to LC3 – the binding of JIP1 to LC3 prevents kinesin processing
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and sustains dynein-mediated retrograde transport, allowing autophagosomes to exit the 
distal axon and travel towards the soma (Fu et al., 2014). Along the axon, autophagosomes 
display robust retrograde movement and go through a maturation process in which they 
increasingly acidify by fusing with late endosomes and lysosomes, ultimately forming 
autolysosomes (Lee et al., 2011; Maday et al., 2012). Fully acidified autolysosomes show 
bidirectional movement and concentrate in the somatodendritic compartment where 
recycling of proteins and lipids is considered more efficient (Maday et al., 2012). 
Autophagosome-lysosome fusion facilitates cargo degradation and is a key step for 
autophagic clearance. A study suggested that F-actin filaments assemble around mature 
autophagosomes and mediate fusion with lysosomes by tethering the two vesicles into 
close contact (Lee et al., 2010). Significantly, the same study reported that the F-actin 
network recruitment was triggered after cortactin deacetylation by HDAC6 and that 
autophagosome-lysosome fusion was blocked in HDAC6 knockout fibroblasts (Lee et al., 
2010). However, a key role for HDAC6 in autophagosome-lysosome fusion in neurons 
conflicted with the fact that HDAC6 knockout mice present increased acetylated -tubulin 
levels in the brain (Bobrowska et al., 2011), are viable and fertile (Zhang et al., 2008), and 
do not develop neurodegenerative phenotypes similar to mice with impaired neuronal 
autophagy (Hara et al., 2006; Komatsu et al., 2006). We thus tested whether HDAC6 
pharmacological inhibition could increase -tubulin acetylation and promote intracellular 
trafficking without blocking neuronal autophagosome-lysosome fusion. Moreover, 
subsequent studies showed that both autophagosomal (Maday et al., 2012) and lysosomal 
(Hendricks et al., 2010) transport in neurons is mediated by the microtubule-based motors 
dynein and kinesin. We thus hypothesized that if HDAC6 inhibition increased -tubulin 
acetylation, then it could promote neuronal autophagic vesicle flux and facilitate mutant 
huntingtin clearance. 
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Our main interests in this study were two-fold:  
1) Assess whether potential differences in mitochondrial dynamics, autophagy and 
mutant huntingtin proteostasis may assist in elucidating differential vulnerability of 
striatal and cortical neurons in HD; 
 
2) Investigate whether HDAC inhibition could modulate mitochondrial dynamics, 
autophagy and mutant huntingtin proteostasis and assess its potential as 
experimental therapeutics to reduce vulnerability of striatal neurons in HD. 
 
The study was performed by addressing the following points: 
Mitochondrial dynamics: 
- Assessment of mitochondrial biogenesis, fission-fusion balance and motility in 
cortical and striatal neurons; 
- Assessment of whether HDAC1 or HDAC6 inhibition modulate mitochondrial 
dynamics in cortical and striatal neurons. 
 
Autophagy: 
- Assessment of whether HDAC6 pharmacological inhibition blocks neuronal 
autophagosome-lysosome fusion; 
- Assessment of whether HDAC6 inhibition promotes neuronal autophagic flux; 
- Comparison of basal autophagic flux in cortical and striatal neurons. 
 
Mutant huntingtin proteostasis (mHtt): 
- Comparison of mHtt aggregation profile in cortical and striatal neurons; 
- Comparison of diffuse mHtt proteostasis in cortical and striatal neurons; 
- Assessment of whether HDAC6 inhibition modulates mHtt aggregation profile or 
diffuse mHtt levels in cortical and striatal neurons. 
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ABSTRACT 
Lysine acetylation is a key post-translational modification known to regulate gene 
transcription, signal transduction, cellular transport and metabolism. Lysine deacetylases 
(KDACs), including classical KDACs (a.k.a. HDACs) and sirtuins (SIRTs), are emerging 
therapeutic targets in neurodegeneration. Given the strong link between abnormal 
mitochondrial dynamics and neurodegenerative disorders (e.g. in Alzheimer, Parkinson and 
Huntington diseases), here we examine the evidence for KDAC-mediated regulation of 
mitochondrial biogenesis, fission-fusion, movement and mitophagy. Mitochondrial 
biogenesis regulation was reported for SIRT1, SIRT3, and class IIa KDACs, mainly via 
PGC-1 modulation. SIRT1 or SIRT3 overexpression rescued mitochondrial density and 
fission-fusion balance in neurodegeneration models. Mitochondrial fission decreased with 
pan-classical-KDAC inhibitors and increased with nicotinamide (pan-sirtuin-
inhibitor/activator depending on concentration and NAD+ conversion). Mitochondrial 
movement increased with HDAC6 inhibition, but this is not yet reported for the other tubulin 
deacetylase SIRT2. Inhibition of HDAC6 or SIRT2 was reported neuroprotective. Mitophagy 
is assisted by the HDAC6 ubiquitin-binding and autophagosome-lysosome fusion promoting 
activities, and was also associated with SIRT1 activation. In summary, KDACs can 
potentially modulate multiple components of mitochondrial dynamics, however, several key 
points require clarification. The SIRT1-biogenesis connection relies heavily in controversial 
caloric restriction (CR) regimes or CR-mimetic drugs, and appears cell-type dependent, 
recommending caution before linking SIRT1 activation with general neuroprotection. Future 
studies should clarify mitochondrial fission-fusion regulation by KDACs, and the interplay 
between HDAC6 and SIRT1 in mitophagy. Also, further studies are required to ascertain 
whether HDAC6 inhibition to enhance mitochondrial trafficking does not compromise 
autophagy or clearance of misfolded proteins in neurodegenerative disorders. 
 
Abbreviations: 
AD, Alzheimer’s disease; CR, caloric restriction; DRG, dorsal root ganglion; Drp1, dynamin-
related protein 1; HAT, histone acetyltransferase; HD, Huntington’s disease; HDAC, histone 
deacetylase; Hsp90, heat shock protein 90; KAT, lysine acetyltransferases; KDAC, lysine 
deacetylase; Mff, mitochondrial fission factor; Mfn, mitofusin; MIEF1, mitochondrial 
elongation factor 1; mtDNA, mitochondrial DNA; NRF, nuclear respiratory factor; OPA1, 
optic atrophy 1; PD, Parkinson’s disease; POMC, proopiomelanocortin; PTM, post-
translational modification; Tfam, mitochondrial transcription factor A.
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Introduction 
1.1 An extended phenotype for lysine acetylation 
Acetylation at the -amino group of lysines is a reversible post-translational modification 
(PTM), crucial for regulating the function of multiple proteins (Yang and Seto, 2008b; 
Choudhary et al., 2009). Lysine acetyltransferases (KATs) and lysine deacetylases 
(KDACs) act in concert to modulate the acetylation status of their targets.  Since lysine 
acetylation prevents positive charges from forming on the amino group, this PTM strongly 
influences protein electrostatic properties (Glozak et al., 2005). The functional 
consequences vary with the relative position of specific lysine residues within the target 
protein, and may manifest as increases as well as decreases in activity, affinity, stability, or 
in protein-protein interaction (Kouzarides, 2000; Glozak et al., 2005). 
Histones were the first substrates identified for eukaryotic KATs and KDACs, explaining 
their common designation as histone acetyltransferases (HATs) and deacetylases 
(HDACs), respectively (Yang and Seto, 2008b). Histone acetylation strongly correlates with 
gene transcription, likely by relaxing chromatin and facilitating access to the transcription 
machinery. Moreover, acetylation of specific lysine residues may directly serve as 
recognition sites for transcription factors (Shahbazian and Grunstein, 2007). Still, when 
considering KDACs non-histone targets, particularly transcription factors, it can no longer 
be generalized that increased acetylation stimulates transcription. Indeed, acetylation of 
transcription factors may increase or decrease their DNA binding affinity depending on 
whether the specific acetylation sites fall directly adjacent or within the DNA-binding domain, 
respectively (Kouzarides, 2000). Thus, KATs and KDACs effects on acetylation and 
transcription provide a versatile mechanism for coupling extracellular signals with the 
genome. 
Non-histone targets regulated by lysine acetylation are mostly comprised by transcription 
factors, but the growing list also includes other key cellular proteins, such as -tubulin, 
importin , heat shock protein 90 (Hsp90), and cortactin, among others (Glozak et al., 2005; 
Zhang et al., 2007). Thus, lysine acetylation plays import regulatory roles not only in 
transcription, but also in signal transduction and cellular transport processes. Further, lysine 
acetylation is a key metabolic regulatory signal, particularly at the level of mitochondria (He 
et al., 2012). 
KDACs in particular have received much attention not only for their physiological roles, 
but also for their involvement in disease states and, consequently, for being a therapeutic 
target (Haberland et al., 2009). In addition to cancer, neurodegenerative disorders are also 
under the scope of possible therapy with drugs targeting KDACs (Kazantsev and 
Thompson, 2008; True and Matthias, 2012). Thus, considering the emerging role of 
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abnormal mitochondrial dynamics in the pathogenesis of neurodegenerative disorders 
(Schon and Przedborski, 2011), in this review we examine the hypothesis that the extended 
phenotype of KDACs activity involves a modulation of mitochondrial dynamics that may 
have therapeutic implications in neurodegeneration. We start by briefly addressing key 
aspects of KDACs, followed by focused analyses on how KDAC modulation impacts 4 
divisions of mitochondrial dynamics: biogenesis, fission-fusion, movement, and mitophagy; 
and how such dynamics are affected in neurodegenerative diseases. 
 
2. KDACs: classes and functions 
The mammalian KDAC superfamily currently holds eighteen members. A core division 
based on homology with yeast KDACs separates ‘classical HDACs’ (zinc-dependent, 
Rpd3/Hda1 homologues) from ‘sirtuins’ (NAD+-dependent, Sir2 homologues). Another 
division establishes four classes based on phylogenetic analysis and sequence homology. 
Classes I, II and IV comprise classical HDACs (with class II further divided into IIa and IIb), 
while class III comprises sirtuins (Yang and Seto, 2008a). 
Class I KDACs (HDAC1, 2, 3, and 8) are predominantly nuclear and widely expressed in 
most tissues, except for HDAC8 that is confined to smooth muscle where it associates with 
-actin and is essential for contractility (Waltregny et al., 2005). HDAC1 and 2 are highly 
homologous and act together as the catalytic subunits of major transcriptional repressor 
complexes such as Sin3, NuRD/NRD/Mi2, and CoREST (Sengupta and Seto, 2004). This 
collaborative spirit of KDACs (Yang and Seto, 2003) also applies to HDAC3, which is 
responsible for the deacetylase activities associated with Class II KDACs, working together 
in a repressor complex with SMRT/N-CoR (Fischle et al., 2002). Class II KDACs display 
tissue-specific expression patterns, being highly expressed in the brain, heart, and muscle. 
Class IIa contains HDAC4, 5, 7, and 9. While full-length HDAC9 remains in the nucleus, 
HDAC4, 5, 7 and a splice variant of HDAC9 (MITR) shuttle between the nucleus and cytosol. 
Phosphorylation and binding to 14-3-3 proteins anchors these HDACs in the cytosol, 
whereas dephosphorylation releases them to return to the nucleus (Kazantsev and 
Thompson, 2008). Class IIb consists of HDAC6 and 10, both primarily cytosolic. HDAC6 is 
unique in containing a C-terminal ubiquitin-binding domain and two functional deacetylase 
domains. Cytosolic HDAC6 deacetylates tubulin, cortactin and HSP90, regulating axonal 
trafficking, cell motility and degradation of misfolded proteins. HDAC6 can also shuttle to 
the nucleus to regulate transcription, with its activity and subcellular localization being 
regulated by acetylation (Liu et al., 2012b). HDAC10 possesses a unique leucine-rich 
domain, interacts with HDAC3, and represses transcription when tethered to a promoter
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(Tong et al., 2002). Class IV consists only of HDAC11, a predominantly nuclear KDAC that 
regulates immune tolerance (Villagra et al., 2009). 
Sirtuins (Class III KDACs) comprise seven mammalian enzymes, SIRT1-7. Their 
deacetylation reaction consumes the cofactor NAD+ while generating nicotinamide plus a 
mixture of 2’ and 3’-O-acetyl-ADP-ribose (Lawson et al., 2010). SIRT1 is present in the 
nucleus, deacetylating histones and several transcription factors. SIRT1 deacetylates and 
activates the transcriptional co-activator PGC-1, a master regulator of mitochondrial 
biogenesis (Nemoto et al., 2005). SIRT1 was reported predominantly cytosolic in the adult 
brain (Li et al., 2008), while PGC1- may also reside in the cytosol being directed to the 
nucleus by stimuli-associated PTMs (Cowell et al., 2007; Little et al., 2010). SIRT2 is 
primarily cytosolic but may also occur in the nucleus where it preferentially deacetylates 
histone H4K16 (Vaquero et al., 2006). SIRT2 shares -tubulin deacetylase activity with 
HDAC6 (Southwood et al., 2007), and has been suggested as the main microtubule 
deacetylase in mature neurons (Maxwell et al., 2011), although it was also reported that 
SIRT2 genetic reduction or ablation has no effect on the acetylation of -tubulin or H4K16 
in mouse brain (Bobrowska et al., 2012). Additionally, SIRT2 is reported to deacetylate the 
transcription factor p65 in the cytosol, thus regulating expression of NF-KB-dependent 
genes (Rothgiesser et al., 2010). SIRT3, 4 and 5 are also called ‘mitochondrial sirtuins’ 
given their subcellular location. SIRT3 is the main deacetylase in the mitochondria, where 
it regulates oxidative phosphorylation, protein synthesis and multiple metabolic pathways. 
The other two mitochondrial sirtuins show weak deacetylase activity, with SIRT5 exhibiting 
pronounced demalonylase and dessuccinylase activity, and the primary activity of SIRT4 
remaining elusive (He et al., 2012). SIRT6 is a nuclear histone H3K9 deacetylase with a 
key role in telomere maintenance and DNA repair (Jia et al., 2012). SIRT7 is a selective 
histone H3K18 deacetylase (Barber et al., 2012) and an activator of RNA polymerase I 
transcription (Ford et al., 2006). 
 
3. The modulation of KDAC activity 
Physiological modulation of KDACs may occur at multiple steps of their life cycle, including 
transcription, pos-transcriptional and proteolytic processing. Additionally, protein-protein 
interactions, co-factor availability, and several PTMs allow dynamic activity control. Most 
KDACs require integration in multi-protein complexes and nuclear localization in order to 
repress transcription. Thus, the activity of such KDACs predictably decreases upon 
interference with complex assembly/stability, reduced availability of interacting proteins 
(e.g. N-CoR for HDAC3), or enhanced nuclear export plus cytosolic retention (e.g. class II 
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KDACs). Conversely, for KDACs acting primarily in the cytosol (e.g. HDAC6 and SIRT2), 
cytosolic retention can increase their activity (Sengupta and Seto, 2004). 
PTM by phosphorylation may either increase (e.g. HDAC1) or decrease (e.g. HDAC8) 
class I enzymatic activity, while regulating class II subcellular localization via binding to 14-
3-3 proteins (Sengupta and Seto, 2004). In turn, PTM by acetylation of the catalytic domain 
and C-terminal region strongly diminishes HDAC1 enzymatic activity (Qiu et al., 2006) and, 
similarly, p300-mediated SIRT2 acetylation reduces its deacetylase activity (Han et al., 
2008). Also, ‘site B’-acetylation decreases HDAC6 tubulin- but not histone-deacetylase 
activity (in vitro), although in situ histone acetylation should decrease since the same PTM 
reduces HDAC6 nuclear import (Liu et al., 2012b). Concerning co-factor availability, the 
NAD+:NADH ratio links cellular metabolic status to class III KDACs’ activity (Sengupta and 
Seto, 2004), whereas zinc is critical for other KDACs’ catalytic activity. Finally, while 
proteolytic degradation of KDACs or their co-activators predictably diminishes their activity, 
specific proteolytic processing may be required for full deacetylase activity (e.g. 
mitochondrial SIRT3; Huang et al., 2010). Thus, multiple physiological processes modulate 
KDAC activity, and some have already assisted drug development. 
Pharmacological KDAC modulators are predominantly inhibitors, with different structural 
requirements for acting on classical KDACs vs. sirtuins. Few activators have been reported, 
except for SIRT1 where several presumed activators have been synthesized (inc. 
SRT1720, SRT2183 and SRT1460), but there is now evidence that these compounds and 
resveratrol are not direct SIRT1 activators (Pacholec et al., 2010), albeit recent data 
suggests that at least some of the physiological effects of these type of compounds may 
occur by “assisted allosteric activation” (Hubbard et al., 2013). Most classical KDACs’ 
inhibitors lack isoform-selectivity as they act by chelating zinc in the catalytic domain. 
Differential interaction with amino acid residues at the entry of the KDAC active site, and 
the mimicking of natural substrates may account for isoform-selective inhibitors, but 
currently little is known about their structure-activity relationships (Bieliauskas and Pflum, 
2008; Marson, 2009; Bertrand, 2010). Most sirtuin inhibitors prevent NAD+ from binding the 
catalytic domain by blocking the required nicotinamide binding site. Alternatively, some 
sirtuin inhibitors compete with the acetylated peptide substrate for its binding site in the 
catalytic domain (Lawson et al., 2010). 
Examples of commonly used KDAC inhibitors of particular relevance for this review are 
as follows. Pan-(classical)-KDAC inhibitors with nanomolar IC50 include the hydroxamate 
derivatives trichostatin A and vorinostat (SAHA; Khan et al., 2008). The short chain fatty 
acids butyrate and valproate are class I and IIa inhibitors in the micro to milimolar range 
(Bieliauskas and Pflum, 2008). Entinostat (MS-275) is an HDAC1-selective inhibitor
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(Khan et al., 2008), whereas tubacin and tubastatin A are HDAC6-selective inhibitors, 
respectively, with ~350- and 1,000-fold selectivity over HDAC1 (Butler et al., 2010). 
Concerning sirtuins, nicotinamide is often used as a pan-sirtuin inhibitor, whereas EX527 
and AGK2 are described as selective SIRT1 and SIRT2 inhibitors, respectively (Lawson et 
al., 2010). 
 
4. Biogenesis 
Mitochondria are continuously renewed by the physiological equilibrium between biological 
generation (biogenesis) and selective degradation through autophagy (mitophagy). 
Increasing the cellular mitochondrial mass is biologically expensive and a long-term 
adaptive response. As such, transient energy demands are met by changes in expression 
of subsets of genes, regulators, or increases in mitochondrial function. Physiological states 
such as endurance training, caloric restriction, and long-term cold exposure (leading to 
adaptive thermogenesis) are reported to promote mitochondrial biogenesis (Hock and Kralli, 
2009; Onyango et al., 2010). 
A complex network of nuclear and mitochondrial transcription factors orchestrate 
mitochondrial biogenesis, a process in which the PGC-1 family of transcriptional 
coactivators plays master regulatory roles. PGC-1 coactivators integrate signals and 
coordinate biological responses allowing cellular adaptation to changes in energy demand, 
including increases in mitochondrial biogenesis, respiration and metabolism (Finck and 
Kelly, 2006). PGC-1 coactivates nuclear respiratory factors (NRFs), which control 
expression of nuclear-encoded mitochondrial structural proteins (Wu et al., 1999). The 
resulting preproteins must be imported, processed and correctly assembled in 
mitochondria, a complex process involving finely tuned posttranscriptional mechanisms and 
the target of rapamycin (TOR) signalling pathway (Devaux et al., 2010). PGC-1-
coactivated NRFs also regulate expression of mitochondrial transcription factor A (Tfam), a 
nuclear-encoded transcription factor crucial for replication, transcription, and maintenance 
of mitochondrial DNA (mtDNA; Kang and Hamasaki, 2005). 
 
4.1 KDACs and mitochondrial biogenesis 
The link between KDACs and mitochondrial biogenesis stems primarily from the 
modulation of PGC-1 by transcriptional or posttranslational mechanisms (Figure 1; Table 
1). PGC-1 transcription is promoted by myocyte-enchancer factor-2 (MEF2) and 
diminished by class IIa KDACs that repress MEF2 activity. Both class IIa KDACs and MEF2 
transcription factors are highly expressed in muscle and brain, and phosphorylation of these 
KDACs promotes their nuclear export, releasing MEF2 to activate PGC-1 transcription
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(Czubryt et al., 2003). Consistently, pan-KDAC inhibitors (trichostatin A and valproate) 
upregulated PGC-1 in neuroblastoma cells (Cowell et al., 2009). Concerning 
posttranslational mechanisms, PGC-1 acetylation by the GCN5 acetyltransferase reduces 
its transcriptional activity (Lerin et al., 2006), whereas deacetylation by SIRT1 activates 
PGC-1 (Nemoto et al., 2005). Interestingly, SIRT1 converges with AMP-activated kinase 
(AMPK) to activate PGC-1; AMPK increases levels of the SIRT1 cofactor NAD+ (Canto et 
al., 2009) and activates PGC-1 by phosphorylation (Jager et al., 2007). Further, these 
posttranslational modifications of PGC-1 activity also promote its own transcription via an 
autoregulatory feedforward loop (Handschin et al., 2003). 
The relationship between SIRT1 and mitochondrial biogenesis has been mostly explored 
in the context of caloric restriction (CR) – a regime reportedly capable of extending life span 
by inducing SIRT1 expression (Cohen et al., 2004). However, studies reporting increased 
mitochondrial biogenesis following CR (Nisoli et al., 2005; Lopez-Lluch et al., 2006; 
Civitarese et al., 2007) were challenged by a recent study showing no increases in 
mitochondrial structural proteins in several rat tissues including the brain (Hancock et al., 
2011). Notwithstanding, CR lacks the selectivity required to scrutinize the pathways linking 
SIRT1 and mitochondrial biogenesis. Alternatively, compounds designated as SIRT1 
activators or “CR mimetic drugs” have been tested and reported to improve mitochondrial 
function and enhance mitochondrial biogenesis and function (Lagouge et al., 2006; Csiszar 
et al., 2009; Funk et al., 2010). Still, there is now evidence that such compounds (inc. 
resveratrol, SRT1720, SRT2183, and SRT1460) do not directly activate SIRT1 (Pacholec 
et al., 2010), but see also the recently suggested “assisted allosteric activation” in (Hubbard 
et al., 2013). Attention has thus turned to AMPK, the SIRT1 partner in activating PGC-1 
(Canto et al., 2009). Some authors argue that AMPK is upstream of SIRT1 in the cascade 
of resveratrol metabolic effects, including mitochondrial biogenesis. Accordingly, AMPK-
deficient mice presented a faulty response to resveratrol and AMPK was considered the 
main resveratrol target (Um et al., 2010). More indirectly, resveratrol was reported to inhibit 
cAMP-degrading phosphodiasterases, increasing cAMP levels and igniting a cascade that 
activates AMPK (Park et al., 2012). In both studies, upstream AMPK activation led to NAD+ 
increases explaining indirect SIRT1 activation by resveratrol (Um et al., 2010; Park et al., 
2012). In contrast, a recent study positions AMPK downstream of SIRT1, provided that 
resveratrol is used in “moderate” doses (Price et al., 2012). In that study, authors argue that 
while high doses of resveratrol may activate AMPK directly, moderate doses increase 
mitochondrial biogenesis in a SIRT1-dependent manner, upstream of AMPK activation. 
Thus, resveratrol indirect activation of AMPK was reported SIRT1-dependent, via 
deacetylation of the AMPK kinase LKB1. Significantly, both high and moderate doses of
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resveratrol failed to increase mitochondrial biogenesis in SIRT1 knockouts (Price et al., 
2012). 
 
4.2 Neuronal mitochondrial biogenesis and KDAC modulation 
The effects of KDAC modulation on neuronal mitochondrial biogenesis have been 
scarcely explored (the wealth of current data on these signalling pathways pertains to non-
neuronal cells). As far as we could find, KDAC activation in neurons (or neuroblastoma 
cells) has been tested only for SIRT1, by means of overexpression or using compounds 
such as resveratrol (with doubtful SIRT1 specificity; Pacholec et al., 2010). Conversely, the 
effects of KDAC inhibition have been tested using SIRT1 deletion, the SIRT1 inhibitor EX-
527, and pan-KDAC inhibitors. Such data are reviewed below, identifying the models and 
with the proviso that neuroblastoma cell lines can behave quite differently from post-mitotic 
neurons. 
 In neuroblastoma cells (Neuro2a), resveratrol was reported to increase mitochondrial 
biogenesis markers through AMPK activation (Dasgupta and Milbrandt, 2007). Authors 
excluded SIRT1 involvement in AMPK activation in neuroblastoma or primary neurons since 
neither SIRT1 inhibitors (sirtinol, splitomycin, and nicotinamide) nor SIRT1 deletion 
attenuated AMPK activation. Interestingly, their study suggests that resveratrol effects are 
neuron-type-dependent. According to their results, AMPK phosphorylation in dorsal root 
ganglion (DRG) neurons is primarily dependent on LBK1 activity, whereas in cortical 
neurons it also requires CamKKB (Dasgupta and Milbrandt, 2007). Still, their study suggests 
that LKB1 activity is SIRT1 independent, which is compatible with some studies (Park et al., 
2012), but contrasts with others reporting SIRT1-dependence (Lan et al., 2008; Price et al., 
2012). Such diverse findings might be explained by cell-type-dependent variations on these 
signalling pathways. Still, regardless of whether resveratrol has multiple targets that might 
modulate mitochondrial biogenesis, it is important to verify if directly targeting SIRT1 activity 
suffices for altering mitochondrial biogenesis in neurons. 
In primary cortical neurons, SIRT1 overexpression or GCN5 acetyltransferase silencing 
increased mitochondrial density in cell bodies and axons (Wareski et al., 2009). Further, 
increased mitochondrial biogenesis by SIRT1 was critically dependent on PGC-1, but 
independent from AMPK. Also, authors showed that SIRT1 effects resulted from 
deacetylating PGC-1 and increasing its transcriptional activity (Wareski et al., 2009).  
In vivo SIRT1 inhibition (with EX-527) increased mitochondrial density in hypothalamic 
proopiomelanocortin (POMC) neurons, without affecting indexes of mitochondrial 
morphology (Dietrich et al., 2010). This was interpreted as an adaptive response to 
decreased inhibitory tone on POMC neurons (Dietrich et al., 2010). Conceivably, the
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heightened activity of uninhibited POMC neurons consumes ATP, increasing the AMP:ATP 
ratio and activating AMPK-dependent mitochondrial biogenesis via PGC-1 
phosphorylation.  
Taken together, these findings suggest that increased SIRT1 activity promotes neuronal 
mitochondrial biogenesis (Wareski et al., 2009), but this may also occur without SIRT1 
involvement (Dasgupta and Milbrandt, 2007), and even following SIRT1 inhibition, at least 
in specific neuronal populations (Dietrich et al., 2010). Significantly, pan-inhibition of KDACs 
(trichostatin A and valproate) in neuroblastoma cells was reported to upregulate PGC-1 
(Cowell et al., 2009), and thus may evoke mitochondrial biogenesis. Clearly, more studies 
are required to elucidate how the AMPK-SIRT1-PGC-1 axis, and other KDACs work in 
neurons to modulate mitochondrial biogenesis. Current evidence suggests that SIRT1 
activity and signalling are highly cell-type dependent, thus advising caution before 
establishing links between SIRT1 activation and general neuroprotection. 
  
4.3. Mitochondrial biogenesis in neurodegeneration 
Multiple neurodegenerative disorders have been associated with abnormal mitochondrial 
biogenesis. Decreases in PGC-1 levels were reported in the context of Huntington (HD), 
Alzheimer (AD), and Parkinson’s (PD) diseases as well as in spinal and bulbar muscular 
atrophy, whereas PGC-1 overexpression was protective in several in vitro and in vivo 
disease models (Jones et al., 2012), although a recent study evidenced that sustained 
PGC-1 overexpression was deleterious to dopaminergic neurons in vivo (Ciron et al., 
2012). Mitochondria number was found decreased in HD patients’ brains, together with 
decreased levels of PGC-1, Tfam and mitochondrial cytochrome c oxidase subunit II (Kim 
et al., 2010a). Moreover, PGC-1 null mice presented neurodegenerative lesions 
predominantly in the striatum (Lin et al., 2004), a particularly vulnerable region in HD 
(Oliveira, 2010). Mitochondria number was also decreased in primary neurons cultured from 
AD mice (Calkins et al., 2011) and in AD patients’ brains (Hirai et al., 2001) together with 
decreased expression of PGC-1, NRF1, NRF2a/2b and Tfam (Sheng et al., 2012). In PD 
patients, both PGC-1 and NRF-1 mRNA were decreased in the substantia nigra and 
striatum (Shin et al., 2011). Furthermore, some PGC-1 polymorphisms have been 
tentatively associated with risk or age of onset of PD (Clark et al., 2011) and HD 
(Taherzadeh-Fard et al., 2009; Weydt et al., 2009; Che et al., 2011), although population 
stratification may have influenced result interpretation (Ramos et al., 2012). 
 PGC-1 thus represents an interesting target to rescue mitochondrial biogenesis in 
neurodegeneration models, yet relatively unexplored in what concerns KDAC modulation. 
Significantly, one study reported that SIRT1 overexpresion restored mitochondrial density
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and increased survival both in PD and HD neuronal models, respectively, expressing A53T 
-synuclein and 120Q huntingtin (Wareski et al., 2009). Further studies are required to 
clarify SIRT1 and other KDACs potential as mitochondrial biogenesis modulators in neurons 
and more specifically in neurodegenerative disorders models.  
Recently, another sirtuin (SIRT3) was reported to stimulate mitochondrial biogenesis 
(Kong et al., 2010; Figure 1). Silencing of the mitochondrial sirtuin SIRT3 in myotubes 
decreased PGC-1-mediated mitochondrial biogenesis, and authors proposed that SIRT3 
might regulate NRF-1 and Tfam activities (Kong et al., 2010). Interestingly, another study 
reported that SIRT3 deacetylates the ribosomal protein MRPL10 down-regulating the 
synthesis of mitochondrial proteins. Consistently, SIRT3 knockout mice presented 
increased expression of mitochondrially-encoded components of oxidative phosphorylation 
(Yang et al., 2010). Thus, whether SIRT3 positively or negatively modulates mitochondrial 
biogenesis remains uncertain and, as far as we could find, unaddressed in neurons. 
Nevertheless, it was recently shown that expression of either SIRT3 or PGC-1 was 
neuroprotective in an amyotrophic lateral sclerosis model, rescuing defects in mitochondrial 
dynamics (Song et al., 2012), specifically fission-fusion dynamics, which is the subject of 
the next section. 
 
5. Fission-Fusion 
Mitochondria are a highly dynamic organelle population that changes size and morphology 
by fusing together or dividing through fission. Mitochondrial fusion enables the exchange of 
mtDNA and other matrix components between mitochondria, rendering protection against 
mtDNA mutations by allowing functional complementation and thus maintaining a healthy 
oxidative phosphorylation system (Chan, 2006; Chen et al., 2007). Mitochondrial fission 
permits mitochondrial separation to daughter cells during mitosis (Taguchi et al., 2007), 
allows segregation of dysfunctional mitochondria to be targeted for mitophagy (Twig et al., 
2008), and enables the mitochondrial size and shape adaptations required for distribution 
in neuronal ramifications (Li et al., 2004; Ishihara et al., 2009; Kageyama et al., 2012; Figure 
1).  
Mitochondrial fusion involves merging of the outer as well the inner mitochondrial 
membranes, a coordinated process assisted by different proteins (Song et al., 2009). 
Mitofusins (Mfn1 and Mfn2) promote outer membrane fusion. These are highly homologous 
GTPases anchored to the outer membrane and able to form homo- or hetero-protein 
complexes (Chen et al., 2003), which allows mitochondrial tethering and fusion in a GTP 
hydrolysis-dependent manner (Ingerman et al., 2005). Significantly, a dominant-negative 
mutation in Drp1 was reported in a newborn with lethal neurodevelopmental abnormalities,
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exhibiting defects in both mitochondrial and peroxisomal fission (Waterham et al., 2007). 
Consistently, Drp1 knockout causes abnormal brain development and embryonic death in 
mice (Ishihara et al., 2009). In yeast, Drp1 attach to mitochondria by binding to Fis1, a 
protein anchored to the mitochondrial outer membrane. In mammals, however, other 
mitochondrial outer membrane proteins seem to take over the Drp1 receptor role. Thus, 
mitochondrial fission factor (Mff) was proposed as an essential factor for Drp1 recruitment, 
mediating fission independently from Fis1 (Otera et al., 2010). Alternatively, mitochondrial 
elongation factor 1 (MIEF1) (Zhao et al., 2011), also identified as MiD49/51 (Palmer et al., 
2011), can bind Drp1 and inhibit its GTP hydrolysis thus promoting fusion instead of fission 
(Oettinghaus et al., 2012). According to such model, Fis1 could promote fission by 
sequestering MIEF1 and consequently unblocking Drp1 GTP hydrolysis (Zhao et al., 2011; 
Oettinghaus et al., 2012). It is also possible that MIEF1 levels determine the outcome, with 
elevated levels compromising selective Drp1 recruitment to constriction sites, leading to its 
uniform distribution, preventing formation of active scission complexes, and thus causing 
fusion instead of fission (Palmer et al., 2011). Recently, Fis1 was also proposed to modulate 
mitochondrial morphology by recruiting the GTPase regulator protein TBC1D15, in a Drp1-
independent manner (Onoue et al., 2012). Thus, while both Drp1 and Fis1 seem to be key 
players in the regulation of mammalian mitochondrial dynamics, whether and how they 
interplay remains to be unravelled. 
 
5.1 KDACs and mitochondrial fission-fusion 
Treatment with different KDAC inhibitors, including pan-, class I- and isoform-selective 
inhibitors, induced mitochondrial elongation in several cell lines, including primary cultures, 
untransformed and cancer cell lines (Lee et al., 2012). Mitochondrial elongation occurred at 
both subtoxic and toxic concentrations, indicating that mitochondrial structural integrity per 
se was not sufficient to protect cells against apoptotic stimuli. Further, the KDAC inhibitors 
increased histone H3 acetylation, decreased Fis1 expression levels, and decreased Drp1 
recruitment to the mitochondria, without altering the levels or acetylation status of the Drp1, 
Mff, Mfn1, Mfn2, and OPA1 proteins (Lee et al., 2012). These findings suggest that 
mitochondrial elongation by KDAC inhibitors resulted from the down-regulation of an 
essential mitochondrial fission mediator, Fis1, which was recently reported as a 
mitochondrial fusion preventer via MIEF1 sequestration (Zhao et al., 2011; Figure 1). 
The concept that KDAC inhibitors decrease Fis1 levels may, at first, seem unexpected 
given the general view that increased histone acetylation should promote transcription and, 
consequently, protein expression. Still, KDACs act on multiple non-histone targets, and 
changes in the lysine acetylation status of transcription factors may either increase or
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decrease their activity (Kouzarides, 2000). Also, KDAC inhibition has been shown to down-
regulate proteins by promoting their ubiquitin-dependent degradation; e.g. DNA 
methyltransferase 1 (DNMT1) is polyubiquitinated when KDAC inhibition hyperacetylates 
the Hsp90 chaperone preventing its interaction with DNMT1 (Zhou et al., 2008). Thus, the 
reported decrease in Fis1 protein levels (Lee et al., 2012) might partly result from increased 
degradation, and not necessarily from decreased transcription. 
Increased mitochondrial fragmentation was reported for human fibroblasts treated with 
nicotinamide (Kang and Hwang, 2009). Similar findings were reported for SIRT1 activators, 
SRT1720 or fisetin, only when SIRT1 expression was intact (Jang et al., 2012). 
Nicotinamide, one of the final products of sirtuin-catalized deacetylation, is frequently used 
as a sirtuin inhibitor. However, it is reported to activate SIRT1 when used in lower 
concentrations (5 mM), since nicotinamide readily converts into the SIRT1 cofactor NAD+ 
via the “NAD+ salvage pathway” (Jang et al., 2012). Together with increased mitochondrial 
fragmentation, nicotinamide reduced the mitochondrial mass, increased mitochondrial 
membrane potential (m), and evoked a time-dependent increase in the levels of Drp1, 
Fis1 and Mfn1. Thus, it was suggested that nicotinamide enhances mitochondrial quality, 
with optimized levels of fission and fusion mediators facilitating separation of defective 
mitochondria for mitophagy (Kang and Hwang, 2009), this being mediated by high 
NAD+:NADH ratio and SIRT1 activation (Jang et al., 2012; Figure 1; Table 2). 
 
5.2 Neuronal mitochondrial fission-fusion and KDAC modulation 
In spite of accumulating evidence for abnormal mitochondrial fission-fusion dynamics in 
neurodegenerative diseases, there is limited data on the regulation of neuronal 
mitochondrial morphology by KDAC modulation. Impaired mitochondrial fusion and smaller 
mitochondrial size was recently reported for motor neurons expressing mutant superoxide 
dismutase (SOD1; Magrane et al., 2012). Accordingly, previous studies reported decreased 
mitochondrial length and disrupted mitochondrial distribution in cell and animal models of 
amyothropic lateral sclerosis (ALS; Magrane et al., 2009; Tradewell et al., 2011; Vande 
Velde et al., 2011), which may stem from decreased OPA1 and increased Drp1 levels in 
mitochondria (Ferri et al., 2010). Concerning KDACs in this context, it was recently reported 
that SIRT3 overexpression rescued mitochondrial fragmentation in cortical neurons 
expressing SOD1G93A (Song et al., 2012). While the mechanisms by which SIRT3 corrects 
mitochondrial morphology remain uncertain, it was proposed that SIRT3 deacetylation of 
cyclophilin D and resulting inhibition of mitochondrial permeability transition may play a 
neuroprotective role (Song et al., 2012).
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5.3. Mitochondrial fission-fusion in neurodegeneration 
Abnormal mitochondrial fission-fusion dynamics, with disequilibrium towards fission has 
been described for multiple neurodegenerative disorders. In the AD brain, reductions in 
Mfn1, Mfn2, OPA1 and Drp1 levels were reported together with increased Fis1 levels (Wang 
et al., 2009). In the context of PD, mutations in the serine/threonine kinase PINK1 or in the 
E3 ubiquitin ligase Parkin are major causes of familial PD, and these two proteins seem to 
functionally interact in the control of mitochondrial dynamics, albeit not in a simple linear 
pathway (Chen and Chan, 2009). Mutant PINK1 is reported to promote mitochondrial fission 
or decrease fusion in mammalian cells. Possible mechanisms are that mutant PINK1 
promotes Drp1 mitochondrial translocation, and interferes with wild-type PINK1 pro-fusion 
effect of increasing the fusion/fission protein ratio (Cui et al., 2010). Parkin acts downstream 
of PINK1, thus mutations in either protein may promote fission by reducing wild-type Parkin-
promoted degradation of Drp1 (Wang et al., 2011a) or Fis1 (Cui et al., 2010). 
HD is also associated with increased mitochondrial fission, with a study in patients brain 
samples reporting increased expression of Drp1 and Fis1, and decreased expression of 
Mfn1, Mfn2, and OPA1 (Shirendeb et al., 2011). This contrasts with findings in several HD 
cell lines reporting no relevant changes in pro-fission or pro-fusion protein levels (Costa et 
al., 2010). Alternatively, the pro-fission phenotype observed in HD cells may stem from 
abnormal Ca2+ homeostasis activating calcineurin, which dephosphorylates Drp1 promoting 
its translocation onto mitochondria (Cereghetti et al., 2008; Costa et al., 2010; Oliveira and 
Lightowlers, 2010). Consistently, a recent study proposes that phosphorylation hinders 
Drp1 oligomerization, reducing its recruitment by Mff or preventing completion of fission-
competent Drp1 spirals, thus inhibiting mitochondrial fission (Strack and Cribbs, 2012). 
Alternatively, increased mitochondrial fission in HD may stem from an abnormal interaction 
between mutant huntingtin and Drp1, which is proposed to increase Drp1 enzymatic activity 
and thus promote mitochondrial fragmentation (Song et al., 2011; Shirendeb et al., 2012). 
Similarly, in AD context, beta amyloid was reported to abnormally interact with Drp1 
(Manczak et al., 2011). 
The growing association of mitochondrial fission and neurodegeneration has sprouted 
the interest in compounds capable of inhibiting mitochondrial fission. Still, while inhibiting 
mitochondrial fission may afford protection against acute injury (Grohm et al., 2012), it is 
becoming clearer that in the long run, inhibiting fission is not beneficial to neurons (Li et 
al., 2004; Kageyama et al., 2012; Sheng and Cai, 2012). Thus, decreasing fission 
probability by epigenetic modulation, namely with KDAC inhibitors (Lee et al., 2012), is 
worth further examination as an alternative to direct fission inhibition.
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6. Movement 
Mitochondrial movement allows their efficient distribution throughout the cell. This is 
particularly relevant in the highly polarized neurons, where ATP diffusion per se would be 
inefficient, and thus mitochondria must travel to supply distant and metabolically demanding 
sites such as synapses, nodes of Ranvier, and active growth cones (Hollenbeck and 
Saxton, 2005). In mammalian cells, mitochondrial transport relies heavily on microtubules, 
motor and adaptor proteins. The kinesin-1 motor family (KIF5) drives anterograde transport 
assisted by adaptors such as Milton orthologues (TRAK1 and TRAK2) linked to 
mitochondrial rho (MIRO), an outer membrane RHO family GTPase and Ca2+ sensor. 
Syntabulin and FEZ1 are other KIF5-mitochondria adaptors, possibly allowing directed 
responses to different physiological signals (Sheng and Cai, 2012). The motor dynein 
typically drives retrograde mitochondrial movement, but may also be involved in 
bidirectional transport. Also, presence of both KIF5 and dynein in the same single 
mitochondrion allows for complex bidirectional movement, possibly coordinated by 
dynactin, which enhances dynein processivity (Cai et al., 2011; Sheng and Cai, 2012). A 
key element for microtubule-based docking of mitochondria in sites of need is syntaphilin, 
which acts as a ‘static anchor’ for axonal mitochondria thus regulating their mobility (Kang 
et al., 2008). 
 
6.1 Microtubule deacetylases and mitochondrial movement 
Microtubules are key cytoskeletal elements involved in neuronal mitochondrial 
trafficking. They are polymers of /-tubulin heterodimers and their functional diversity can 
be regulated by PTMs (Hammond et al., 2008; Janke and Kneussel, 2010). Acetylation of 
-tubulin at lysine 40 was reported as a specific PTM that enhances recruitment of kinesin-
1 and dynein/dynactin motor complexes to microtubules, and stimulates anterograde and 
retrograde transport (Reed et al., 2006; Dompierre et al., 2007). KATs such as the ARD1-
NAT1 (ADP-ribosylation factor domain protein1 in complex with N-terminal 
acetyltransferase), and the Elongator complex, where shown capable of acetylating -
tubulin (Janke and Kneussel, 2010; Creppe and Buschbeck, 2011). Subsequently, TAT1 
was proposed as the major and possibly the sole -tubulin K40 acetyltransferase in 
mammals and nematodes (Shida et al., 2010). Conversely, two KDACs, specifically HDAC6 
and SIRT2, were found to interact and deacetylate -tubulin in vitro and in vivo (Hubbert et 
al., 2002; North et al., 2003; Zhang et al., 2003; Figure 1; Table 3). 
HDAC6 and SIRT2 were reported to co-localise along the microtubule network and 
coimmunoprecipitate. Also, silencing of HDAC6 or SIRT2 alone sufficed to evoke tubulin 
hyperacetylation (North et al., 2003). Taken together with the report that tubulin does not
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bind HDAC6 or SIRT2 individually (Nahhas et al., 2007), these data supported the 
hypothesis that HDAC6 and SIRT2 act interdependently in a protein complex. There are 
other studies, however, suggesting they are unlikely binding partners in vivo given their 
different expression profiles in brain cells, with HDAC6 predominating in neurons (esp. 
Purkinje cells) and SIRT2 in oligodendrocytes (Li et al., 2007; Southwood et al., 2007). Still, 
there is also evidence for SIRT2 expression in hippocampal, cortical and striatal neurons in 
vitro (Pandithage et al., 2008; Luthi-Carter et al., 2010), and a study reporting abundant 
neuronal expression of SIRT2, particularly in the adult brain (Maxwell et al., 2011). In such 
study, authors allude to a previous observation that tubulin is “not hyperacetylated” in the 
brains of HDAC6-deficient mice, and explain it with the possibility that abundant SIRT2 
compensates for lack of HDAC6 (Maxwell et al., 2011). Such allusion, however, contrasts 
with the original publication in HDAC6-deficient mice, where the respective authors state 
that no significant increase in tubulin acetylation was found because, in the brain, tubulin is 
“already highly acetylated” in wild-type animals, and therefore, HDAC6 inactivation has no 
visible impact on acetylation levels (Zhang et al., 2008). Still, a recent study reports 
significant increases in -tubulin K40 acetylation in HDAC6-/- mice (Govindarajan et al., 
2013). 
SIRT2-mediated modulation of mitochondrial trafficking has not been reported, as far as 
we could find in the literature. Nevertheless, there are reports that SIRT2 inhibition does 
modulate neuronal physiology, being neuroprotective in disease models highly associated 
with mitochondrial dysfunction, such as PD and HD. Specifically, SIRT2 inhibition protected 
against -synuclein toxicity, decreasing dopaminergic neuron death in both in vitro and in 
vivo (Drosophila) PD models, with the suggested mechanisms being that increased -
tubulin acetylation promotes coalescence of misfolded proteins into larger protective 
inclusions (Outeiro et al., 2007). SIRT2 inhibition was also found protective in a striatal 
neuron model of HD, by a mechanism involving decreased sterol biosynthesis (Luthi-Carter 
et al., 2010). Such mechanism has been questioned partly due to contrasting evidence that 
low sterol/cholesterol levels are associated with HD neurodegeneration (Valenza and 
Cattaneo, 2010). Thus, further studies are required to elucidate the putative neuroprotective 
role of SIRT2 inhibition and its effects on mitochondrial dynamics. 
HDAC6 inhibition promoted both retrograde and anterograde mitochondrial 
movement in hippocampal neurons, together with increased tubulin acetylation and 
KIF5-mitochondria association. Further, Glycogen Synthase Kinase 3 (GSK3) 
inhibition: reduced HDAC6 phosphorylation at serine 22; increased tubulin acetylation; 
and enhanced mitochondrial movement. Thus, leading to the proposal that GSK3 may 
regulate HDAC6 activity by phosphorylation (Chen et al., 2010). The implications are that
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misregulation of HDAC6, presumably overactivated by GSK3-mediated phosphorylation, 
might underlie impaired mitochondrial transport. Significantly, mitochondrial and vesicular 
trafficking impairment in AD models was associated with abnormal GSK3 activation (Rui 
et al., 2006; Decker et al., 2010). Taken together, these data suggest that HDAC6 might be 
involved in linking GSK3 to the trafficking impairment in AD. In fact, evidence suggests 
that HDAC6 is involved in trafficking abnormalities in several neurodegenerative disorders, 
as addressed below. 
 
6.2. KDAC modulation of trafficking and neurodegeneration 
In neurodegenerative diseases such as Huntington and Alzheimer’s, current evidence 
suggest a beneficial role for HDAC6 inhibition. Indeed, HD patients’ brain samples exhibit 
decreased tubulin acetylation; and cellular HD models present compromised microtubule-
dependent transport, suggesting that transport might be restored by tubulin deacetylase 
inhibition (Dompierre et al., 2007). Consistently, selective HDAC6 inhibition with tubacin, 
but not HDAC1 inhibition with MS275, increased -tubulin acetylation at lysine 40; thus 
enhancing KIF5 and dynein recruitment to microtubules, and promoting bidirectional 
transport in striatal cell lines. Further, KDAC inhibitors capable of inhibiting HDAC6 were 
shown to enhance transport-dependent BDNF release in cortical neurons expressing either 
wild type or mutant N-terminal huntingtin constructs (Dompierre et al., 2007). Similarly, 
decreased -tubulin acetylation (Hempen and Brion, 1996) and increased HDAC6 levels 
(Ding et al., 2008) were reported for the AD brain, suggesting a role in abnormal 
mitochondrial trafficking in this disease. Also, in hippocampal neurons challenged with 
amyloid-, HDAC6 inhibition with tubastatin A enhanced bidirectional mitochondrial motility, 
rescuing transport and reducing mitochondrial fragmentation (Kim et al., 2012). More 
recently, HDAC6 deletion was reported to improve memory function in AD mice without 
affecting amyloid- plaque load (Govindarajan et al., 2013). Significantly, HDAC6 deletion 
protected primary neurons from mitochondrial trafficking defects induced by amyloid- 
derived difusable ligands, and enhanced mitochondrial distribution in the hippocampi of AD 
mice (Govindarajan et al., 2013). 
Degeneration of the peripheral nervous system may also benefit from HDAC6 inhibition, 
as shown for Charcot-Marie-Tooth disease models with altered mitochondrial transport. In 
this context, mice expressing mutant heat-shock protein HSPB1 presented decreased 
acetylated tubulin and severe axonal transport deficits. Significantly, DRG neurons from 
symptomatic HSPB1S135F mice exhibited decreased mitochondrial number and motility in 
their neurites. Pharmacological HDAC6 inhibition in vitro and in vivo rescued the 
mitochondrial number and motility phenotype in DRG neurons. Further, in vivo HDAC6
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inhibition improved motor performance, together with improved 
electrophysiological/histological parameters, suggesting that it might be a useful therapeutic 
approach in peripheral neuropathies (d'Ydewalle et al., 2011). 
In spite of the above evidence, HDAC6 inhibition is unlikely a universal solution for 
abnormal axonal transport. Interestingly, evidence from neuroinflammation models points 
towards another HDAC – the normally nuclear-located HDAC1 - as playing a critical role in 
the onset of axonal damage and mitochondrial transport abnormalities, not ameliorated by 
HDAC6 inhibition. Neuroinflammatory stimuli (glutamate plus TNF) were reported to evoke 
a Ca2+-dependent nuclear export of HDAC1 (Kim et al., 2010b). Interestingly, pan-classical-
KDAC inhibition improved neuronal Ca2+ recovery following glutamate receptor (NMDAR) 
ativation (Oliveira et al., 2006). Ca2+-dependent nuclear export appears to confer a cytosolic 
gain of function to HDAC1, namely, binding -tubulin and motor proteins (KIF5 and KIF2A), 
thus impairing their ability to transport cargo such as mitochondria, leading to localized 
neurite swelling and degeneration (Kim et al., 2010b). These toxic effects were partly 
rescued by preventing HDAC1 nuclear export, or by pharmacological inhibition of HDAC1 
with MS275, but not by HDAC6 inhibition with tubacin (Kim et al., 2010b). Hence, it seems 
that different KDACs may impair mitochondrial transport as a function of different 
pathological triggers, explaining the opposite findings of inhibiting HDAC6 vs. HDAC1 in 
models of HD (Dompierre et al., 2007) vs. neuroinflammation (Kim et al., 2010b; Figure 1). 
Still, inhibiting KDACs for rescuing mitochondrial transport must be balanced against 
putative interference with other roles, such as the role of HDAC6 in mitophagy.  
 
7. Mitophagy 
The selective degradation of defective mitochondria prevents them from releasing oxidants 
and apoptosis triggers, thus being critical for neuronal health and survival. The mitophagy 
machinery engulfs and digests small fusion-deficient mitochondria exhibiting sustained 
depolarization (Twig and Shirihai, 2011). A key mitophagy regulator is the PINK1-Parkin 
signalling pathway. PINK1 acts as m sensor, recruiting Parkin to depolarized 
mitochondria, thus triggering the mitophagy machinery. Mechanistically, PINK1 is normally 
imported into polarized mitochondria and constitutively degraded by PARL (presenilin-
associated rhomboid-like protein). In bioenergetic incompetent mitochondria, however, 
PINK1 is no longer degraded and accumulates in the outer membrane where it can recruit 
Parkin (Jin et al., 2010). Through its E3 ubiquitin ligase activity, Parkin ubiquitinates 
mitochondrial proteins like VDAC1 (Geisler et al., 2010) and MIRO (via an interplay with 
Pink1 that arrests damaged mitochondria; Wang et al., 2011b; Liu et al., 2012a), and also 
ubiquitinates fusion mediators like mitofusins (Gegg et al., 2010). Thus, depolarized
Guedes-Dias and Oliveira, 2013 
 
 
47 
 
mitochondria are rendered fusion-deficient and with a coating that attracts the ubiquitin-
binding autophagic components, p62 and HDAC6 (Lee et al., 2010a; Youle and Narendra, 
2011; Ding and Yin, 2012; Figure 1). 
 
7.1 KDACs and mitophagy 
HDAC6 is reported to play a key role in the quality control autophagy of protein 
aggregates and mitochondria (Lee et al., 2010b; Lee et al., 2010a). HDAC6 has the capacity 
to bind polyubiquitinated proteins and also dynein motors, thus linking target recognition 
with its transport to aggresomes (Kawaguchi et al., 2003; Ouyang et al., 2012). Moreover, 
HDAC6 facilitates aggresome clearance (Iwata et al., 2005; Pandey et al., 2007) by 
controlling autophagosome-lysosome fusion (Lee et al., 2010b; Figure 1; Table 3). 
The HDAC6 ubiquitin- and dynein-binding motifs are distinct from the tubulin deacetylase 
domain that is selectively targeted by HDAC6 inhibitors (Haggarty et al., 2003), which were 
neuroprotective in several disease models (Dompierre et al., 2007; d'Ydewalle et al., 2011; 
Kim et al., 2012). Nevertheless, there is evidence that a functional HDAC6 deacetylase 
domain is required for aggresome formation, autophagosome-lysosome fusion and 
autophagic turnover (Kawaguchi et al., 2003; Iwata et al., 2005; Pandey et al., 2007; Lee et 
al., 2010b). Thus, although HDAC6 inhibition enhances mitochondrial and vesicle 
trafficking, it may hinder mitophagy as well as the turnover of misfolded proteins. Still, when 
reduced axonal trafficking is the main problem for a given disease state, HDAC6 inhibition 
might be beneficial if compensatory mechanisms allow for adequate protein and 
mitochondria turnover. 
SIRT1 may partly compensate for HDAC6 inhibition. Autophagosome-lysosome fusion 
requires cytosolic HDAC6 catalytic activity to deacetylate cortactin, which mediates the 
necessary F-actin remodelling (Lee et al., 2010b). Meaningfully, in the adult brain, SIRT1 is 
predominantly located in the cytosol (Li et al., 2008), thus being in a position to interact with 
cortactin. In fact, HDAC6 and SIRT1 were both shown to bind and deacetylate cortactin 
independently, but may also work cooperatively or competitively, with their relative 
dominance being cell type dependent (Zhang et al., 2009; Figure 1). Further, although 
HDAC6 knockout mice are reported to develop ubiquitin-positive brain aggregates (Lee et 
al., 2010b), they are also described as developing normally, being fertile and viable, without 
obvious brain and spinal cord abnormalities (Zhang et al., 2008). Thus, it is conceivable that 
increased activity of SIRT1 might compensate for the consequences of HDAC6 
knockout/inhibition on cortactin acetylation, and consequently on autophagosome-
lysosome fusion.
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SIRT1 activation was associated with mitophagy induction in human fibroblasts. Indeed, 
treatment with SIRT1 activators or with nicotinamide (5 mM - a concentration that converts 
to NAD+ and activates SIRT1; Jang et al., 2012) was reported to accelerate mitophagy at 
least in part by inducing mitochondrial fragmentation. Consistently with quality control 
mitophagy activation, treated cells exhibited a decreased mitochondrial mass but increased 
m; together with increased levels of the autophagosomal marker LC3-II, and higher 
number of mitochondria-associated LC3 puncta and lysosomes (Kang and Hwang, 2009; 
Jang et al., 2012). While the exact mechanisms downstream of SIRT1 activation remain 
uncertain, findings are consistent with the ongoing degradation of small depolarized 
mitochondria, which are preferential targets for mitophagy (Twig and Shirihai, 2011). 
Further studies are required to clarify the interplay between HDAC6 and SIRT1 in the 
regulation of mitophagy. While HDAC6 modulation may have therapeutic potential in 
neurodegeneration (Li et al., 2011), the effects of HDAC6 inhibition on axonal trafficking 
must be balanced against the fact that misfolded proteins aggregates are a hallmark of 
several neurodegenerative diseases (Ross and Poirier, 2004). Therefore, HDAC6 inhibition 
aimed at promoting neuronal mitochondrial trafficking should be further explored to test for 
implications in autophagolysosome formation and clearance in neurons. 
 
7.2 Mitophagy in Neurodegeneration 
Parkinson’s disease has taken the lead in the research on mitophagy impairment, partly 
due to the links between the PINK1-Parkin pathway and familial forms of this 
neurodegenerative disorder (Vives-Bauza and Przedborski, 2011). Wild-type Parkin is 
selectively recruited to dysfunctional mitochondria and promotes their autophagy (Narendra 
et al., 2008). Parkin recruitment depends on functional PINK1, and loss of function 
mutations in PINK1 or Parkin can block mitophagy (Geisler et al., 2010). Thus, PD 
neurodegeneration may at least partly stem from impairment in selective mitochondrial 
clearance, leading to the accumulation of dysfunctional organelles. 
In Alzheimer’s disease brains, the area of intact mitochondria was found decreased in 
vulnerable neurons, together with increased mtDNA and proteins in vacuoles associated 
with lipofuscin. This increase in mitochondrial degradation products suggested either 
increased mitophagy or decreased proteolytic turnover (Hirai et al., 2001). Indeed, it has 
been proposed that AD mitochondria are susceptible to increased autophagic degradation 
(Moreira et al., 2007a, b), but it is still uncertain whether increased mitophagy is a protective 
response or contributing to pathology, possibly in a synergistic manner with dysfunctional 
fission-fusion dynamics (Santos et al., 2010). Interestingly, increased Parkin expression in 
AD mice was shown to decrease intracellular amyloid- levels and extracellular plaque
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deposition, while also promoting autophagic clearance of defective mitochondria 
(Khandelwal et al., 2011). 
Huntington’s disease cellular models were reported to exhibit defects in cargo 
recognition by autophagic vacuoles, preferentially affecting organelle sequestration, and 
leading to the accumulation of abnormal mitochondria. Further, an abnormal interaction 
between mutant huntingtin and the autophagic adaptor p62 was proposed to cause the 
cargo recognition failure (Martinez-Vicente et al., 2010). Interestingly, it has been reported 
that HDAC6 is required for efficient autophagic degradation of aggregated huntingtin (Iwata 
et al., 2005). Thus, the modulation of HDAC6 activity might be an interesting strategy to 
improve the clearance of both mutant huntingtin and abnormal mitochondria in HD. 
 
8. Concluding Remarks 
Lysine deacetylases are emerging therapeutic targets in neurodegeneration. Current 
evidence suggests that their modulation, namely with epigenetic drugs such as KDAC 
inhibitors, may assist correction of abnormal mitochondrial dynamics in neurodegenerative 
diseases. The enhancement of mitochondrial biogenesis, movement, quality control 
mitophagy, and the restoration of fission-fusion balance have all been proposed as 
neuroprotective strategies. Concerning mitochondrial biogenesis, it is predominantly 
reported enhanced by SIRT1 activation. Still, recent findings suggest caution in interpreting 
data generated with uncertain SIRT1 activators. Future studies should help clarify the 
SIRT1-biogenesis connection and provide further mechanistic data for the role of SIRT3 
and other KDACs in this process. Excessive mitochondrial fission is consistently reported 
for multiple neurodegenerative diseases, but arresting this crucial physiological event is also 
detrimental to neurons. Thus, decreasing fission probability with KDAC inhibitors is worth 
further examination as an alternative to direct fission inhibition. Abnormal mitochondrial 
transport has been associated with both HDAC6 and HDAC1 activities depending on the 
pathological trigger. In different neurodegenerative disease models, HDAC6 inhibition was 
shown to rescue trafficking abnormalities. Still, given the ubiquitin-binding and 
autophagosome-lysosome fusion promoting activities of HDAC6, the consequences of 
HDAC6 inhibition upon autophagy and clearance of misfolded proteins require further 
exploration. Conceivably, when reduced axonal trafficking is the main problem for a given 
disease state, HDAC6 inhibition might be beneficial if compensatory mechanisms allow for 
adequate autophagy and protein turnover. 
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Figure 1. Modulation of mitochondrial dynamics by KDACs. Biogenesis: Involvement of 
classical KDACs and sirtuins on mitochondrial biogenesis pathways. Movement: Role of 
tubulin deacetylases HDAC6 and SIRT2 in regulating mitochondrial trafficking. Also, nuclear 
export and trafficking impairment by HDAC1 following injury. Fission-Fusion: Mediators of 
mitochondrial fission and fusion, and putative roles of KDAC modulation. Mitophagy: 
HDAC6 recognizing ubiquitinated mitochondria, assisting transport and promoting 
autophagosome-lysosome fusion via cortactin deacetylation together with SIRT1.
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Table 1. KDACs and mitochondrial biogenesis 
 
Corresponding references: 
[65] – Price et al., 2012 
[186] – Kawashima et al., 2011 
[61] – Csiszar et al., 2009 
[69] – Dietrich et al., 2010 
[68] – Wareski et al., 2009 
[60] – Lagouge et al., 2006 
[85] – Yang et al., 2010 
[84] – Kong et al., 2010 
[50] – Cowell et al., 2009 
[49] – Czubryt et al., 2003 
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Table 2. KDACs and mitochondrial fission-fusion 
 
Corresponding references: 
[112] – Jang et al., 2012 
[186] – Kawashima et al., 2011 
[69] – Dietrich et al., 2010 
[111] – Kang and Hwang, 2009 
[86] – Song et al., 2012 
[109] – Lee et al., 2012 
[158] – d’Ydewalle et al., 2011 
[157] – Kim et al., 2011 
[50] – Cowell et al., 2009 
[49] – Czubryt et al., 2003 
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Table 3. KDACs and mitochondrial movement or mitophagy. 
 
Corresponding references: 
[157] – Kim et al., 2012 
[158] – d’Ydewalle et al., 2011  
[159] – Kim et al., 2010 
[152] – Chen et al., 2010 
[149] – Govindarajan et al., 2013 
[186] – Kawashima et al., 2011 
[111] – Kang and Hwang, 2011 
[167] – Lee et al., 2010 
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ABSTRACT 
Striatal neurons are vulnerable to Huntington’s disease (HD). Impaired mitochondrial 
dynamics and decreased levels of acetylated alpha-tubulin are associated with HD, but it is 
unclear how these might contribute to the preferential degeneration of striatal neurons. Both 
HDAC1 and HDAC6 inhibitors rescued mitochondrial trafficking in neurological disease 
models, but their effects on neuronal mitochondrial fission-fusion or biogenesis remain 
undetermined. Also, inhibition of the alpha-tubulin deacetylase HDAC6 as a therapeutic 
strategy for HD is controversial – studies in neurons suggest it may compensate intracellular 
transport deficits, whereas data from cell-lines suggest it may impair autophagosome-
lysosome fusion and mutant huntingtin (mHtt) degradation. Using primary cultures of rat 
striatal and cortical neurons, we show that striatal mitochondria are less motile and more 
balanced towards fission than cortical mitochondria, and that striatal neurons present lower 
autophagic flux compared to the less HD-vulnerable cortical neurons. The HDAC1 inhibitor 
MS-275 decreased mitochondrial fission and levels of the fission-associated Fis1 protein. 
The HDAC6 inhibitor tubastatin (TBA) increased acetylated alpha-tubulin levels, inducing 
mitochondrial motility and fusion in striatal neurons to levels observed in cortical neurons. 
Neither MS-275 nor TBA modified mitochondrial biogenesis. Importantly, TBA did not block 
neuronal autophagosome-lysosome fusion. Instead, TBA increased autophagic flux and 
reduced diffuse mHtt in striatal neurons, possibly by promoting transport of initiation factors 
to sites of autophagosomal biogenesis. This study identifies pharmacological HDAC6 
inhibition as a potential strategy to reduce the vulnerability of striatal neurons to HD.
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INTRODUCTION 
Huntington’s disease (HD) is a fatal neurodegenerative disorder caused by polyglutamine 
(polyQ) expansion mutations in the huntingtin protein. Although ubiquitously expressed, 
mutant huntingtin (mHtt) induces selective neurodegeneration that is most harmful to striatal 
neurons (Ross and Tabrizi, 2011). There are several reports suggesting that mHtt can 
induce mitochondrial dysfunction (Oliveira, 2010a,b Costa and Scorrano, 2012; Reddy and 
Shirendeb, 2012), but it is not clear how that might contribute to preferential striatal 
neurodegeneration. One hypothesis is that striatal neurons are intrinsically vulnerable to 
mitochondrial dysfunction. Indeed, even without mHtt, striatal neurons show increased 
susceptibility to oxidative phosphorylation defects (Pickrell et al., 2011), and to calcium-
induced mitochondrial permeability transition (Oliveira and Goncalves, 2009) when 
compared to cortical neurons. It remains an open question whether striatal and cortical 
neurons also present intrinsic differences in mitochondrial dynamics that might influence 
their differential vulnerability. 
Histone deacetylase (HDAC) inhibitors are experimental therapeutics for 
neurological disorders, primarily intended to increase histone acetylation and rescue 
transcriptional dysregulation (Kazantsev and Thompson, 2008), or to increase -tubulin 
acetylation and rescue impaired intracellular transport (Hinckelmann et al., 2013). Pan-
HDAC inhibitors and, particularly, selective HDAC1 or HDAC6 inhibitors, also seem capable 
of rescuing mitochondrial dysfunction (Guedes-Dias and Oliveira, 2013). Pan-HDAC 
inhibitors rescued mitochondrial calcium-handling in neurons from HD mice (Oliveira et al., 
2006), whereas HDAC1 (Kim et al., 2010) and HDAC6 inhibitors (d'Ydewalle et al., 2011; 
Kim et al., 2012) rescued mitochondrial trafficking in different neurological disease models. 
In non-neuronal cells, HDAC1 inhibitors increased mitochondrial biogenesis (Galmozzi et 
al., 2013) and reduced mitochondrial fission (Lee et al., 2012). These properties might be 
therapeutically useful for neurological disorders, but since HDAC inhibitor effects are often 
cell-type dependent (Dietz and Casaccia, 2010) it remains unknown whether HDAC1 or 
HDAC6 inhibitors modulate mitochondrial biogenesis and fission-fusion balance in neurons. 
Use of HDAC6 inhibition as a therapeutic strategy for HD has been controversial. 
HDAC6 is unique for its primary tubulin-deacetylase and ubiquitin-binding activities 
(Simões-Pires et al., 2013). Studies in neuronal HD models support HDAC6 inhibition as a 
neuroprotective strategy capable of compensating intracellular transport deficits (Dompierre 
et al., 2007), whereas studies in cell-lines indicate that HDAC6 inhibition/knockout may 
disrupt autophagosome-lysosome fusion (Lee et al., 2010) and prevent mHtt degradation 
(Iwata et al., 2005), predicting detrimental effects in HD. However, HDAC6-knockout mice 
show no evidence of brain abnormalities (Zhang et al., 2008; Govindarajan et al., 2013),
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failing to support a role for HDAC6 in autophagosome-lysosome fusion, which would be 
expected to impair autophagy and cause neurodegeneration (Nixon, 2013). It is therefore 
important to clarify whether pharmacological HDAC6 inhibition affects neuronal autophagy 
and mHtt proteostasis. 
Primary cultures of striatal and cortical neurons are frequently used to model 
differential vulnerability in HD (Oliveira and Goncalves, 2009; Tsvetkov et al., 2013). Here 
we investigated whether these neurons present intrinsic differences in mitochondrial 
biogenesis, trafficking and fission-fusion dynamics, and whether such dynamics are 
modulated by treatment with HDAC1 or HDAC6 inhibitors. We also used live-imaging to 
determine whether pharmacological HDAC6 inhibition affects autophagosome-lysosome 
fusion in neurons, and how it impacts mHtt proteostasis in striatal and cortical neurons.
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MATERIALS AND METHODS 
Plasmids and antibodies. Plasmids: mito-DsRed2 (mtDsRed; Michael Ryan, La Trobe 
University, Australia), mCherry-EGFP-LC3B (Jayanta Debnath, University of California, 
USA - Addgene 22418; N'Diaye et al., 2009), EGFP-Httex1Q74 (David Rubinsztein, 
University of Cambridge, UK - Addgene 40262; Narain et al., 1999) and pmaxGFP (GFP; 
Amaxa). Primary antibodies and dilutions for Western blotting: anti-acetylated-histone-
H3K9 (ab10812; 1:500), anti-acetylated--tubulin [6-11B-1] (ab24610; 1:5000), anti--actin 
[mAbcam 8226] (ab8226; 1:2000), anti-Fis1 (ab71498; 1:250), anti-mitofusin2 [NIAR164] 
(ab124773; 1:1000), anti-succinate dehydrogenase complex subunit A [2E3GC12FB2AE2] 
(SDHA; ab14715; 1:1000) were from Abcam; anti--tubulin [11H10] (#2125; 1:1000), anti-
histone-H3 [96C10] (#3638; 1:1000), anti-LC3A/B (#4108; 1:1000) and anti-SQSTM1/p62 
(#5114; 1:500) were from Cell Signaling; anti-OPA1 (612606; 1:1000) was from BD 
Biosciences; anti-acetylated-cortactin (09-881, 1:400) was from Merck-Millipore.  
 
Drugs and reagents. The HDAC1 inhibitor MS-275 and the HDAC6 inhibitor tubastatin A 
(TBA) (Selleck Chemicals) were dissolved in dimethyl sulfoxide (DMSO), present at 0.1% 
in all treatment and control conditions (‘solvent’). With the proviso that studies in cells 
typically require higher concentrations, studies with the isolated enzymes suggest that 1 µM 
MS-275 preferentially inhibits HDAC1 (IC50 = 0.2 µM), but may also inhibit HDAC9 (IC50 = 
0.5 µM) and partly HDAC2 (IC50 = 1.2 µM) (Khan et al., 2008). Still, other studies suggest 
that 1 µM MS-275 has no inhibitory activity over HDAC9 (Bradner et al., 2010). TBA is 
HDAC6 selective – isolated enzyme IC50 values are 0.015 μM for HDAC6, 0.9 μM for 
HDAC8, 16.4 μM for HDAC1 and > 30 μM for other HDAC isoforms (Butler et al., 2010). 
Here we use MS-275 and TBA always at 1 µM, as previously described for neurons (Baltan 
et al., 2011; d’Ydewalle et al., 2011). Fura-2 AM, MitoTracker Green FM and cell culture 
reagents were from Invitrogen. All other reagents were from Sigma-Aldrich, unless 
otherwise stated. 
 
Neuronal culture and transfection. Sister cortical and striatal primary cultures were 
generated from Wistar rat embryos as previously described (Oliveira et al., 2006; Oliveira 
and Goncalves, 2009), in full compliance with European Union directive 2010/63/EU. 
Cortical and striatal cells were plated at 103 cells per mm2 on polyethylenimine coated glass 
coverslips and maintained in culture medium (Neurobasal supplemented with 2% B27, 1% 
fetal bovine serum, 1% penicillin/streptomycin and 1% GlutaMAX) at 37ºC, 5% CO2. 
Cytosine arabinoside (10 M) was added 48 h after plating to prevent glial proliferation. For 
neuronal transfection, culture medium was replaced with a mixture of 450 l Neurobasal
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(with 1 Glutamax) and 50 l Opti-MEM (containing 0.3-0.5 g DNA, 0.5 l Lipofectamine 
LTX and 0.5 l Plus Reagent; Invitrogen). Following 30-45 min incubation (37ºC, 5% CO2) 
neurons were washed twice with Dulbecco’s modified Eagle medium prior to restoring the 
conditioned culture medium. The average transfection efficiency was 5%, allowing single 
neuron identification for analyzing neurites, mitochondria, LC3-vesicles, or mHtt levels, 
without excessive overlap between cells. 
 
Gene transcription and mitochondrial DNA (mtDNA) levels. For mRNA quantification, 
total RNA was isolated with illustra RNAspin Mini kit (GE Healthcare) and cDNA prepared 
with iScript cDNA Synthesis Kit (Bio-Rad). qPCR was performed with iQ5 MyiQ System 
(Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad). GAP-43 primers: forward 5’-
CCATGCTGTGCTGTATGAGAAG, reverse 5’-TCCTCCGGTTTGACACCATC. RPL13A 
primers: forward 5’-GGATCCCTCCACCCTATGACA, reverse 5’-
CTGGTACTTCCACCCGACCTC. For mtDNA levels, total DNA was extracted with DNeasy 
Blood & Tissue Kit (Qiagen). Primers for mtDNA (MTND1 gene): forward 5’-
AATACGCCGCAGGACCATTC, reverse 5’-GGGGTAGGATGCTCGGATTC. Primers for 
nuclear DNA (nDNA; eEF1A gene): forward 5’-AGCCAAGTGCTAATGTAAGTGAC, 
reverse 5’-CCCTTGAACCACGGCATCTA. Relative quantifications were performed with 
the Pfaffl method (correcting for measured efficiencies) (Pfaffl, 2001). 
 
Western blotting. Neurons were rinsed with ice-cold phosphate-buffered saline (PBS), 
lysed in buffer containing 150 mM NaCl, 0.5 deoxycholate, 0.1 SDS, 1 Triton X-100, 
50 mM Tris (pH 8.0), and protease inhibitors. Protein was quantified by Bradford assay (Bio-
Rad). Samples were boiled in Laemmli buffer, loaded at 20-25 µg per lane in polyacrylamide 
gels, electrophoresed under reducing conditions, and electroblotted to polyvinylidene 
difluoride membranes (PVDF; Millipore). Membranes were blocked in PBS with 0.05 
Tween 20 (PBST) containing 5 non-fat dry milk, then incubated overnight at 4ºC with 
primary antibodies (diluted in PBST with 5 BSA – bovine serum albumin), followed by 
washing in PBST and incubation with respective horseradish peroxidase conjugated 
antibodies for detection by enhanced chemiluminescence. 
 
Neurite outgrowth in young neurons. Neurons with 3 days in vitro (DIV) were imaged 24 
h post-transfection with GFP. Imaging (488 nm excitation) was performed at 37ºC, 5 CO2, 
using an inverted microscope equipped with LSM700 confocal scanner, 20 Plan-
Apochromat 0.8 NA air objective, and Definite Focus (Axio Observer.Z1 system; Zeiss). 
Sholl analysis (Sholl, 1953; ImageJ) with 1 µm spaced concentric circles, was performed
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on binary images (following background correction and thresholding), to calculate branching 
peak (intersection maxima) and total outgrowth (summed intersections). 
 
Dendrite outgrowth, mitochondrial occupancy, size and number, in mature neurons. 
Neurons at 10 DIV were fixed (4% paraformaldehyde, 37ºC for 15 min) after 24 h 
transfection with GFP and mtDsRed, and imaged with an inverted Eclipse TE300 
microscope system (Nikon; 60 PlanFluor 0.85 NA air objective; Polychrome II 
monochromator, TILL Photonics; C6790 CCD camera and Aquacosmos 2.5 software, 
Hamamatsu). At 10 DIV, the extensive axonal sizes, branching and inter-neuronal overlaps 
precluded full single-neuron tracings, focusing our quantitative analyses in dendrites and 
proximal axon. Sholl analysis with 1 µm-spaced circles was used to calculate dendrite 
branching peaks (intersection maxima), outgrowth (summed intersections), and 
mitochondrial fractional occupancy (mitochondrial intersections divided by dendrite 
intersections). Particle analysis (ImageJ) was used to calculate mitochondrial number and 
size (Feret diameter) in neurons divided into ‘mitochondrial regions’, each comprising the 
area between two circles of increasing radii: -region (15-30 µm); -region (30-80 µm); -
region (80-130 µm). 
 
Mitochondrial motility. Neurons at 10 DIV were loaded with Fura-2 AM (4 M; for labeling 
neurites; 380nm excitation) and MitoTracker Green (50 nM; for labeling mitochondria; 
488nm excitation; Oliveira, 2011) for 30 min, washed twice and live imaged (5s intervals for 
10 min) in recording media (133 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1 mM MgCl2, 1 mM 
Na2SO4, 0.4 mM KH2PO4, 15 mM glucose, 20 mM HEPES, pH 7.4) at 37ºC. The proportion 
of motile mitochondria was assessed via kymographs (20 representative lines per video; 
Multi Kymograph – J. Rietdorf and A. Seitz). 
 
LC3-vesicle dynamics. Neurons expressing mCherry-EGFP-LC3B were live imaged at 8-
10 DIV (48 h post-transfection) in culture media at 37ºC, 5% CO2, using an Axiovert 200M, 
with LSM510 and a 63 Plan-Apochromat 1.4 NA oil objective (Zeiss). Combining acid-
sensitive EGFP (488 nm excitation) with acid-insensitive mCherry (543 nm excitation) 
allows distinction of autophagosomes (EGFP + mCherry signal) from autolysossomes 
(mCherry signal only) (Pankiv et al., 2007). LC3-positive vesicles were counted in whole 
somata -stacks. Cytoplasmic volume was measured with 3D Objects Counter (F. 
Cordelières), deleting nuclei and using diffuse EGFP-LC3 fluorescence to define somatic 
boundaries. Vesicle motility parameters were analyzed with MTrackJ in 10 min videos at 3 
s intervals, acquiring on the mCherry channel only (minimum velocity threshold was 0.1
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m/s; Lee et al., 2011). Vesicles crossing the first axonal branch towards the soma were 
expressed as events per 5 min (retrograde flux). 
 
Immunofluorescence. Neurons were fixed with 4% paraformaldehyde for 15 min at 37ºC, 
washed 3 times in PBS, permeabilized and blocked with 0.1% Triton X-100 and 3% BSA in 
PBS (Abdil) for 30 min. Neurons were then incubated for 1 h with primary antibody (anti-
acetylated-cortactin, 1:150 in Abdil), and washed 3 times with 0.1% Triton X-100 in PBS, 
followed by 1 h incubation with Alexa Fluor 488 conjugated secondary antibody (Invitrogen; 
A-11034; 1:200 in Abdil). After assembly in fluorescent mounting medium (Dako), neurons 
were imaged with the aforementioned Eclipse TE300 system, ensuring non-saturating 
identical equipment settings for intensity comparisons between treatments. 
 
Huntingtin proteostasis. Neurons were transfected with mHtt encoding plasmid at 5 DIV 
(Tsvetkov et al., 2013), and live imaged at 24 and 48 h post-transfection in culture medium 
at 37ºC, 5% CO2. Fluorescently tagged mHtt exon 1 (EGFP-Httex1Q74) was excited at 488 
nm and imaged at 20 with the aforementioned Axio Observer.Z1 system, ensuring non-
saturating identical equipment settings for fluorescence intensity comparisons. After 
imaging at 24 h post-transfection (6 DIV), neurons were treated with either solvent or TBA 
and re-imaged 24 h later (7 DIV; 48h post-transfection). Transfected neurons were 
screened for presence of aggregates and their location (soma and neurites), and their 
counts expressed in percentage of EGFP-positive neurons. Diffuse mHtt levels were 
measured by the average somatic EGFP fluorescence in neurons without visible 
aggregates. 
 
Image processing and data analysis. Image processing was performed with ImageJ 
(http://rsbweb.nih.gov/ij/; National Institutes of Health) using the indicated plugins. 
Numerical data calculations were automated in Excel spreadsheets (Microsoft). Other data 
analyses and statistical calculations were performed using Prism 6.0 (GraphPad Software). 
Two-tailed Student’s t test was used when comparing two groups, one-way ANOVAs with 
Dunnet’s post-hoc when comparing three or more groups, and two-way ANOVA with 
Sidák’s post-hoc when testing the interaction plus the main effects of region (cortical  
striatal) and treatment (solvent  drugs). Curve fit comparisons in nonlinear regression 
analyses were performed with extra sum-of-squares F test. Unless otherwise stated, data 
are mean  SEM of the n specified in figure legends. 
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RESULTS 
Striatal and cortical neurons show intrinsic differences in mitochondrial dynamics 
Neurons are highly polarized post-mitotic cells that distribute their mitochondria throughout 
neurites (Ruthel and Hollenbeck, 2003). To investigate whether mitochondrial dynamics 
differ between striatal and cortical neurons, we compared their neurite outgrowth and 
mitochondrial biogenesis along development. Young striatal and cortical neurons presented 
similar dendrites and branching peaks (Fig. 1A,B at 3 DIV), but total outgrowth was lower 
in striatal neurons as their axons were shorter (Fig. 1F – white boxes). Consistently, growth-
associated protein 43 (GAP-43) mRNA levels were also lower in young striatal neurons, 
reaching cortical levels during maturation (Fig. 1C). Mature cortical neurons were larger and 
more branched than striatal neurons, but the average dendrite outgrowth of the two 
populations was similar (Fig. 1A,B at 10 DIV; Fig. 2A,B – white bars). 
To determine whether mitochondrial biogenesis differed between the two cell types, 
we measured changes in mitochondrial DNA relative to nuclear DNA, which is predicted to 
remain stable in post-mitotic cells. Mitochondrial DNA increased during maturation of both 
neuronal populations, with differences matching their neurite outgrowth (Fig. 1D). The 
proportion of neurite length occupied by mitochondria was not significantly different in 
striatal and cortical neurons (Fig. 2Ci), while mitochondrial motility was significantly reduced 
in striatal neurons (Fig. 2D – white bars). These data therefore suggest that mitochondrial 
biogenesis and trafficking are modulated to maintain a constant mitochondrial volume 
occupancy in neurons. 
To compare the mitochondrial fission-fusion balance, we measured mitochondrial 
size and number in three concentric ‘mitochondrial regions’ progressively away from the 
soma (-, -, and -regions; Fig. 3A). Mitochondrial size was significantly affected by 
distance from soma, decreasing from the - towards the -region (Fig. 3B). Mitochondria in 
striatal neurons were smaller and more numerous than in cortical neurons (Fig. 3B,C – white 
bars). These data, together with identical mitochondrial occupancy (Fig. 2Ci) and higher 
levels of fission-associated protein in striatal neurons (Fis1/SDHA, Fig. 3D, Table 1), 
indicate that the striatal mitochondria population is intrinsically more balanced towards 
fission. 
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The HDAC inhibitors MS-275 and TBA modulate the fission-fusion balance of 
neuronal mitochondria without altering its biogenesis 
To assess the effects of HDAC inhibitors on mitochondrial dynamics we measured changes 
in neuronal outgrowth and mitochondrial biogenesis. We confirmed the efficacy of 72 h 
treatment with the HDAC1 inhibitor MS-275 (1 µM; Baltan et al., 2011) the HDAC6 inhibitor 
TBA (1 µM; d'Ydewalle et al., 2011) by detecting increased acetylation, respectively, of the 
HDAC1-substrate histone-H3K9 or the HDAC6-substrate -tubulin-K40, in comparison to 
the solvent control (0.1% DMSO; Fig. 1E). Early cortical outgrowth was significantly reduced 
by MS-275 treatment and increased by TBA treatment; early striatal outgrowth was not 
significantly modified by these treatments (3 DIV; Fig. 1F). In mature cultures, MS-275 had 
no significant effect on dendrite branching, reducing outgrowth only in striatal neurons; TBA 
had no significant effect on the branching or outgrowth of mature neurons (10 DIV; Fig. 
2A,B). These results suggest that the effects of HDAC1 and HDAC6 inhibitors on neuronal 
outgrowth are developmental- and neuron-type dependent. 
The level of mitochondrial biogenesis of striatal or cortical neurons was not affected 
by treatment with either MS-275 or TBA, as judged from unaltered mtDNA/nDNA ratios at 
3 or 10 DIV (Fig. 1G). Treatment with MS-275 increased mitochondrial volume occupancy 
near cortical somata (Fig. 2Cii), without significantly affecting mitochondrial motility (Fig. 
2D). Moreover, MS-275 increased mitochondrial size in cortical and striatal neurons (Fig. 
3B), and reduced mitochondrial number in striatal neurons (Fig. 3C). Taken together with 
the observation that MS-275 decreases Fis1 levels in cortical and striatal neurons, and also 
the levels of the fusion-associated OPA1 and Mfn2 in cortical neurons (Table 1), these 
results suggest that MS-275 shifts the mitochondrial fission-fusion balance by limiting fission 
and not by promoting fusion. 
Treatment with TBA significantly increased the proportion of motile mitochondria in 
cortical and striatal neurons (Fig. 2D), without modifying fractional occupancy (Fig. 2Cii,iii). 
In cortical neurons, TBA had no significant effect on mitochondrial size and number (Fig. 
3B,C). In striatal neurons, however, TBA increased the size and reduced the number of 
mitochondria (Fig. 3B,C). Since TBA did not alter mitochondrial fission-fusion protein levels 
(Table 1), these results suggest that increasing the low mitochondrial motility of striatal 
neurons with TBA treatment increases the probability of mitochondrial contact and fusion.
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Figure 1. Neuronal outgrowth and mitochondrial biogenesis during maturation of 
cortical and striatal neurons. (A) Representative neurons at 3 DIV are shown whole; 10 
DIV neurons are truncated at ~200 µm from soma. Inset shows neurite and mitochondrial 
labeling. (B) Branching peak in maturing cortical and striatal neurons; n  10-20 neurons 
from 3-5 independent cultures. (C) GAP-43 mRNA and (D) mitochondrial DNA levels in 
maturing neurons; n = 3 independent cultures. (E) Immunoblot showing -tubulin and 
histone-H3 acetylation in 3 DIV neurons treated with 1 M TBA and/or 1 M MS-275 for 72 
h. (F) Sholl analysis at 3 DIV, total intersections with 1 m-spaced circles; data are shown 
as box-plots with median and interquartile distance of n = 42-50 neurons from 5 independent 
cultures, per treatment condition; *p < 0.05, **p < 0.01 to solvent-treated cortical neurons. 
(G) Mitochondrial DNA levels in fold to respective solvent control (0.1% DMSO) at 3 or 10 
DIV; n = 3 independent cultures.
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Figure 2. Dendrite morphology and mitochondrial dynamics in mature neurons. (A-
D) Cortical and striatal neurons at 10 DIV, following treatment with solvent, 1 M MS-275, 
or 1 M TBA for 72 h. (A) Intersections with dendrites (top) or mitochondria (bottom) as a 
function of distance from soma (Sholl analysis with log-normal curve fits); (B) Dendrite 
branching peak and outgrowth; (C) mitochondrial fractional occupancy with distance from 
soma (one-phase decay curve fit); n  11-17 neurons from 3 independent cultures, per 
treatment condition. (D) Mitochondrial motility and representative kymograph; n  3-10 
independent cultures (296-417 individual mitochondria analyzed per treatment condition in 
each culture). *p < 0.05, **p < 0.01 to solvent-treated cortical neurons; #p < 0.05 to solvent-
treated striatal neurons.
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Figure 3. Mitochondrial fission-fusion balance in cortical and striatal neurons. (A) 
Representative neuron divided in encircled ‘mitochondrial regions’ , , , and respective 
radii. Insets show mitochondria (mtDsRed) and neurites (GFP) with 10 µm scale bars. (B, 
C) Mitochondrial size and number quantification within the , , and  regions of 10 DIV 
neurons, treated with solvent, 1 M MS-275 or 1 M TBA for 72 h. Black triangles denote 
significant effects of region ( towards ) on mitochondrial size (p < 0.05, ANOVA linear 
trend). n  13-21 neurons from 3 independent cultures, per treatment condition. (D) 
Immunoblot for mitochondrial fission-fusion proteins (see Table 1 for quantifications).
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Table 1. Mitochondrial fission-fusion indicators 
 
Striatal / Cortical Cortical Striatal 
 
solvent / solvent MS-275 / solvent TBA / solvent MS-275 / solvent TBA / solvent 
Fis1 / SDHA  1.35  0.07, p < 0.01  0.71  0.09, p  0.08 0.85  0.11, p  0.23  0.79  0.08, p  0.10 0.91  0.13, p  0.46 
OPA1 / SDHA      1.11  0.04, p  0.07   0.68  0.02, p < 0.01 0.97  0.08, p  0.66      0.84  0.09, p  0.14 0.96  0.17, p  0.64 
Mfn2 / SDHA       1.11  0.07, p  0.20  0.77  0.08, p  0.10 1.03  0.11, p  0.87      0.93  0.04, p  0.19 1.05  0.07, p  0.48 
Quantification of protein levels by immunoblot densitometry. Arrows indicate direction of differences greater than 20% (p ≤ 0.10, ratio paired t test). Data 
are mean  SEM of the ratios to solvent; n  3-7 independent cultures.  
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The HDAC6 inhibitor TBA does not block neuronal autophagosome-lysosome fusion, 
while increasing LC3-vesicle retrograde flux and autophagic turnover 
To investigate the effects of HDAC6 inhibition of neuronal autophagosome-lysosome fusion, 
we imaged live neurons expressing mCherry-EGFP-LC3. Under control conditions 
(solvent), the vast majority of somatodendritic LC3-vesicles were autolysosomes (acidified, 
with loss of EGFP-fluorescence; Fig. 4Ai), indicating that constitutive autophagosome-
lysosome fusion is highly efficient in neurons (Boland et al., 2008). Inhibition of the 
lysosomal proton pump with bafilomycin A1 (BAF) impaired LC3-vesicle acidification (EGFP 
fluorescence retained; Fig. 4Aiii) and lysosomal digestion (p62 accumulation; BAF: Fig. 4B, 
Table 2), as predicted for impaired autophagosome-lysosome fusion (Klionsky et al., 2012). 
Treatment with TBA increased tubulin acetylation (Fig. 4D) without impairing LC3-vesicle 
acidification (Fig. 4Aiv,v) or p62 digestion (Fig. 4B, Table 2). These results show that TBA 
inhibits HDAC6-mediated tubulin deacetylation without blocking neuronal autophagosome-
lysosome fusion. 
Since cortactin deacetylation by HDAC6 was found necessary for constitutive 
autophagosome-lysosome fusion in fibroblasts (Lee et al., 2010) we monitored the levels of 
acetylated cortactin in neurons, where its function is mostly unknown (Catarino et al., 2013). 
In cortical and striatal neurons, in situ acetyl-cortactin immunoreactivity presented a 
punctate distribution in dendrites (Fig. 4C), with some neurons presenting immunoreactivity 
in the nuclear region as previously reported for hippocampal neurons (Catarino et al., 2013). 
Treatment with TBA increased in situ acetyl-cortactin immunoreactivity in neurons (Fig. 4C). 
No changes were detected by immunoblotting for acetyl-cortactin although acetyl-tubulin 
levels were clearly increased (Fig. 4D). 
To investigate the dynamics of neuronal LC3-vesicles, we monitored their direction 
and velocity in distal axons (>400 µm from soma), their retrograde flux through the first 
axonal branch (a critical converging point for vesicles moving towards the soma), and we 
also quantified somatic autolysosomes (Fig. 5). Under control conditions, most LC3-vesicles 
in distal axons were autophagosomes (mCherry- and EGFP-positive; Fig. 5A) and exhibited 
robust retrograde movement (Fig. 5B,C), as previously described (Lee et al., 2011; Maday 
et al., 2012). Treatment with TBA modified neither LC3-vesicle direction (Fig. 5C) nor 
velocity (Fig. 5C,D), but significantly increased the retrograde flux through the first axonal 
branch (Fig. 5E,F), and the number of somatic autolysosomes (Fig. 5G,H), suggesting that 
more autophagosomes are being formed and converted into autolysosomes while moving 
towards the soma. TBA treatment also increased LC3-II, while decreasing p62 levels (Fig. 
4B, Table 2), as predicted for increased formation of autophagosomes together with 
enhanced lysosomal digestion (Klionsky et al., 2012), indicating that TBA increases
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autophagic flux. We next investigated whether these effects of TBA treatment had 
significant consequences for the proteostasis of mHtt in neurons. 
 
The HDAC6 inhibitor TBA promotes clearance of diffuse mHtt in striatal neurons, 
which show a lower autophagic flux than cortical neurons 
We compared mHtt proteostasis in neurons expressing an EGFP-tagged mHtt construct 
with 74Q (Fig. 6A). The overall proportion of neurons with mHtt aggregates at 24 h was 
higher for cortical than for striatal neurons, increasing at identical rates for both populations 
towards 48 h (Fig. 6Bi). Within aggregate-containing neurons, the proportion with neuritic 
aggregates at 24h was similar and increased over time without significant differences 
between cortical and striatal neurons (Fig. 6Ci). In neurons without aggregates, diffuse mHtt 
levels were higher at 24 h and decreased over time for cortical neurons, whereas the 
opposite pattern was observed for striatal neurons where diffuse mHtt continued to increase 
towards 48 h (Fig. 6Di). 
To test possible mechanisms behind this differential mHtt proteostasis, we probed 
striatal and cortical neurons for intrinsic differences in autophagic flux. Following interruption 
of digestion with bafilomycin, more p62 accumulated in cortical than in striatal neurons 
(Table 2 – BAF), indicating that autophagic flux is lower in striatal neurons. Induction of 
autophagy with rapamycin evoked more pronounced increases in LC3-II and decreases in 
p62 levels in striatal neurons (Table 2 – RAP), respectively indicating proportionally higher 
increases in autophagosome formation and in lysosomal digestion (Klionsky et al., 2012), 
which is consistent with a lower autophagic flux in striatal neurons prior to treatment with 
rapamycin. 
Treatment with the HDAC6 inhibitor TBA did not modify the overall proportion of 
cortical or striatal neurons with mHtt aggregates (Fig. 6Bii), while showing a trend for 
reducing mHtt aggregates in striatal neurites (Fig. 6Cii). Moreover, treatment with TBA 
significantly reduced diffuse mHtt levels in striatal neurons (Fig. 6Dii). These data suggest 
that pharmacological HDAC6 inhibition in neurons increases the clearance of diffuse mHtt.
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Figure 4. Neuronal autophagosome-lysosome fusion and autophagy markers. (A) 
Representative somata of cortical neurons expressing mCherry-EGFP-LC3, imaged live 
following the indicated treatments: RAP – 10 nM rapamycin, BAF – 25 nM bafilomycin A1, 
TBA – 1 µM tubastatin A. (B) Immunoblot for autophagy markers: neurons were incubated 
with solvent, TBA or RAP for 24 h before protein extraction; BAF was present only for the 
last 6 h of incubation (see Table 2 for quantifications). (C) Representative 
immunofluorescence images of acetyl-cortactin in cortical neurons treated with solvent or 
TBA for 24 h. (D) Immunoblot for acetyl-cortactin and acetyl--tubulin with respective 
quantifications relative to -actin; n = 2 independent cultures. 
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Figure 5. Neuronal LC3-vesicle dynamics. (A) mCherry- and EGFP- positive LC3-
vesicles in distal axons of live cortical neurons. (B) Time-lapse (top) and kymograph 
(bottom) showing stationary (arrow) and moving (arrowhead) LC3-vesicles in a distal axon 
(only the mCherry channel is shown). (C) Movement direction of LC3-vesicles in distal 
axons of cortical neurons treated with solvent or TBA (1 M, 24 h); n = 21-26 axonal sections 
from 20-21 neurons from 4 independent cultures. (D) Retrograde LC3-vesicle velocity in 
distal axons of cortical neurons treated with solvent or TBA; n = 92-109 vesicles from 19-
20 neurons from 4 independent cultures. (E) LC3-vesicles (arrowheads) moving through 
the first axonal branch towards the soma. (F) Retrograde flux of LC3-vesicles through the 
first axonal branch of cortical neurons treated with solvent or TBA; n  11-14 neurons from 
2 independent cultures. (G) Cortical soma showing different number of LC3-vesicles 
depending on the focal plane (left vs. right). (H) Quantification of autolysosomes (mCherry 
signal only) in cortical neuronal somata Z-stacks imaged after 24 h treatment with solvent, 
TBA or rapamycin (RAP, 10 nM); n  13-68 neurons from 2-7 independent cultures. **p < 
0.01 vs. solvent. Scale bars: 10 µM. 
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Figure 6. Huntingtin proteostasis in cortical and striatal neurons. (A) Representative 
mHtt (EGFP-Httex1Q74) expression patterns: somatic (1) and neuritic aggregates (3,5); 
diffuse (2,4). (B-D) (i) region  time: comparison of solvent-treated cortical and striatal 
neurons from 24 to 48 h; (ii) region  treatment: comparison of cortical and striatal neurons 
at 48 h, following 24 h treatment with solvent or 1 µM TBA. (B) Neurons with mHtt 
aggregates in percentage of EGFP-positive neurons; (C) Neurons with neuritic aggregates, 
in percentage of aggregate-containing neurons; n = 3 independent experiments with 599-
852 EGFP-positive neurons per experimental group. (D) Diffuse mHtt levels in neurons 
without visible aggregates; n = 86-220 neurons per experimental group, from 3-4 
independent cultures. Interaction, region, and time p values are from two-way ANOVAS; 
**p < 0.01 to solvent-treated cortical neurons; ##p < 0.01 to solvent-treated striatal neurons. 
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Table 2. Autophagy markers in cortical and striatal neurons 
 
LC3-II / -actin p62 / -actin 
 
Cortical Striatal Cortical Striatal 
TBA / solvent  1.48  0.10, p < 0.05  1.25  0.04, p < 0.01     0.88  0.20, p  0.52  0.82  0.02, p < 0.05 
BAF / solvent  1.79  0.12, p < 0.05  2.43  0.21, p < 0.01  1.90  0.18, p < 0.05      1.22  0.17, p  0.34 
RAP / solvent      1.18  0.11, p  0.24  1.72  0.17, p < 0.05      0.66  0.13, p  0.14  0.58  0.08, p < 0.05 
Quantification of protein levels by immunoblot densitometry. Arrows indicate direction of differences (p < 0.05, ratio paired t test). Data are mean  SEM 
of the ratios to solvent; n  3-4 independent cultures.  
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DISCUSSION 
Here we show that striatal and cortical neurons present intrinsic differences in mitochondrial 
biogenesis, fission-fusion and trafficking dynamics, modulated to maintain identical 
mitochondrial volume occupancy. Mitochondria in striatal neurons are more balanced 
towards fission and less motile than those in cortical neurons. The HDAC1 inhibitor MS-275 
or the HDAC6 inhibitor TBA did not modify mitochondrial biogenesis, but both altered the 
mitochondrial fission-fusion balance – MS-275 reduced fission, whereas TBA increased 
mitochondrial motility and promoted fusion. Pharmacological HDAC6 inhibition with TBA did 
not block neuronal autophagosome-lysosome fusion, but increased autophagic flux and 
reduced diffuse mHtt in striatal neurons. These data provide insight into HD striatal 
vulnerability and experimental therapeutics with HDAC inhibitors, as addressed below.  
 
Intrinsic differences in mitochondrial dynamics may contribute for striatal 
vulnerability to HD 
Mitochondrial dysfunction, including impaired calcium handling, excessive fission and 
reduced trafficking, are associated with HD pathophysiology (Oliveira, 2010a,b; Costa and 
Scorrano, 2012; Reddy and Shirendeb, 2012). Although direct interactions with mHtt may 
cause mitochondrial dysfunction (Panov et al., 2002; Shirendeb et al., 2012; Yano et al., 
2014), the widespread distribution of mHtt in the brain argues against such interactions as 
the basis for the selective striatal vulnerability seen in HD (Han et al., 2010). Here we show 
that mitochondria in striatal neurons are intrinsically more balanced towards fission and 
display lower motility than in cortical neurons. This pre-existent higher fission may contribute 
towards striatal neurons being precociously affected by the increase in mitochondrial 
fragmentation that occurs in HD (Shirendeb et al., 2011). Similarly, a pre-existent lower 
motility may contribute to a more striking inhibition of mitochondrial trafficking by diffuse 
mHtt in striatal (Orr et al., 2008) than in cortical neurons (Chang et al., 2006). 
Together with previous findings of increased striatal susceptibility to oxidative 
phosphorylation defects (Pickrell et al., 2011) and to calcium-induced mitochondrial 
permeability transition (Brustovetsky et al., 2003; Oliveira and Goncalves, 2009), the 
present data support the hypothesis that striatal neurons have an intrinsic vulnerability to 
mitochondrial dysfunction contributing to their preferential degeneration in HD.  
 
HDAC1 and HDAC6 inhibitors modulate mitochondrial fission-fusion balance in 
neurons 
MS-275, an inhibitor of HDAC1, increased cortical and striatal mitochondria size while 
decreasing Fis1 levels, indicating that HDAC1 inhibition reduces mitochondrial fission in
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neurons by the same mechanism reported for cell-lines (Lee et al., 2012). MS-275 
concentrated mitochondria near cortical somata, likely by preventing the size adaptation 
required for distribution and not by increasing biogenesis, as we found no changes in 
mtDNA/nDNA levels in MS-275-treated neurons. This contrasts with data from cell-lines 
showing increased mitochondrial biogenesis following MS-275 treatment, presumably 
because we used an HDAC1 selective concentration of 1 µM MS-275, whereas cell-lines 
were treated with 5 µM MS-275 – also inhibiting HDAC3, thereby increasing PGC-1 
expression and biogenesis (Galmozzi et al., 2013). 
TBA, the inhibitor of HDAC6, increased tubulin acetylation and mitochondrial motility 
in cortical and striatal neurons, consistent with increased motor affinity to acetylated 
microtubules (Dompierre et al., 2007), and with previous studies in hippocampal (Chen et 
al., 2010) or dorsal-root-ganglion neurons (d'Ydewalle et al., 2011). We also show that TBA 
shifts the mitochondrial fission-fusion balance of striatal neurons towards more fusion, 
possibly because increasing microtubule-dependent movement increases fusion probability 
(Liu et al., 2009; Cagalinec et al., 2013), particularly when mitochondrial contact probability 
is otherwise reduced by low motility. Decreasing fission or increasing fusion might be useful 
pharmacological properties to counteract excessive fission in diseases such as HD (Costa 
et al., 2010; Guo et al., 2013). However, sufficient fission must remain for suitable 
mitochondrial distribution and quality-control (Twig et al., 2008; Jahani-Asl et al., 2010; 
Oliveira and Lightowlers, 2010). HDAC6 inhibition might be a better approach to modulate 
the mitochondrial fission-fusion balance. Indeed, fission reduction with MS-275 also 
reduced neurite outgrowth, whereas TBA increased tubulin acetylation (shown decreased 
in HD brains; Dompierre et al., 2007), and promoted fusion in striatal neurons without 
affecting neurite outgrowth.  
 
HDAC6 is not essential for autophagosome-lysosome fusion in neurons, and HDAC6 
inhibition might stimulate autophagosomal biogenesis 
In a previous study using HDAC6-knockout fibroblasts, HDAC6 was found necessary for 
constitutive autophagosome-lysosome fusion by a mechanism involving cortactin 
deacetylation (Lee et al., 2010). However, both HDAC6 and cortactin deacetylation were 
found dispensable for autophagosome-lysosome fusion when the same fibroblasts were 
starved (Lee et al., 2010). Here we show that TBA treatment increases tubulin acetylation 
in neurons without impairing LC3-vesicle acidification or p62 digestion, thus indicating that 
HDAC6 is dispensable for neuronal autophagosome-lysosome fusion. 
HDAC6 inhibition with TBA contrasts with HDAC6-knockout by presumably allowing 
for ubiquitin-binding and for some deacetylase domain 1 (DD1) activity as TBA was
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designed against HDAC6 DD2 (Butler et al., 2010). Nevertheless, studies showing no 
obvious brain abnormalities in HDAC6-knockout mice (Zhang et al., 2008; Govindarajan et 
al., 2013) are consistent with HDAC6 being dispensable for neuronal autophagosome-
lysosome fusion. The contrasting finding in neurons and fibroblasts may also stem from 
differences in cortactin distribution. Neuronal cortactin concentrates in dendritic spines 
(Hering and Sheng, 2003) being scarce in axons (Racz and Weinberg, 2004). Since most 
neuronal autophagosomes initiate distally and fuse with lysosomes along the axon (unlike 
throughout the cytosol in fibroblasts; Maday et al., 2012; Maday and Holzbaur, 2014), 
scarce axonal cortactin suggests it is less important for autophagosome-lysosome fusion in 
neurons than in fibroblasts. 
TBA-treated neurons exhibited higher LC3-vesicle retrograde flux, more somatic 
autolysosomes, and increased LC3-II with decreased p62 levels. These findings are 
compatible with the stimulation of autophagosomal biogenesis (Klionsky et al., 2012). 
Consistently, previous studies found that starvation induced a more robust increase in LC3-
II conversion and long-lived protein degradation in HDAC6-knockout fibroblasts than in 
control fibroblasts (Lee et al., 2010). How might HDAC6 inhibition stimulate 
autophagosomal biogenesis? We hypothesize that the associated increase in microtubule-
dependent transport promotes initiating factor arrival to sites of autophagosomal formation. 
Such factors might include the endoplasmic reticulum subdomains containing DFCP1 
(Double-FYVE-Containing-Protein-1; involved in neuronal autophagosomal biogenesis: 
Maday and Holzbaur, 2014) (Gonzalez and Couve, 2014), the c-Jun-N-terminal-protein-
Kinase-1 (JNK1; required for autophagosomal biogenesis: Wei et al., 2008), and the JNK1-
interacting protein (JIP1; required for autophagosomal exit from distal axons: Fu et al., 
2014) (Geeraert et al., 2010). 
 
Striatal and cortical neurons differ in mHtt proteostasis, and HDAC6 inhibition 
promotes diffuse mHtt clearance 
Here we found higher initial levels of diffuse mHtt and more pronounced aggregation in 
cortical than striatal neurons, consistent with higher initial levels predicting aggregate 
formation (Arrasate et al., 2004; Miller et al., 2010), and with more aggregates in cortex than 
striatum in HD patients (Gutekunst et al., 1999). In the absence of aggregates, our data 
suggest that diffuse mHtt accumulates over time in striatal but not in cortical neurons, which 
is consistent with the mean lifetime of mHtt being higher in striatal than cortical neurons 
(Tsvetkov et al., 2013), and with recent data showing preferential accumulation of mHtt in 
the striatum (Wade et al., 2014). The correlation of diffuse mHtt levels with the risk of 
neuronal death suggests that the toxic species reside within the diffuse fraction (Arrasate
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et al., 2004; Miller et al., 2010) and, therefore, that treatments capable of reducing diffuse 
mHtt should hold neuroprotective potential. 
The HDAC6 inhibitor TBA reduced diffuse mHtt in striatal neurons, without altering 
the proportion of cortical or striatal neurons with mHtt aggregates. These present findings 
in neurons apparently contrast with studies in HDAC6-knockout cell-lines showing reduced 
clearance of protein aggregates (Kawaguchi et al., 2003) and reduced autophagic 
degradation of mHtt (Iwata et al., 2005). Our findings agree, however, with other studies in 
neurons, where HDAC6 inhibition alleviated abnormal tau accumulation (Cook et al., 2012), 
and with in vivo HDAC6-knockout in R6/2 mice showing no increase in mHtt aggregates 
(Bobrowska et al., 2011). As previously suggested (Bobrowska et al., 2011), some of the 
effects of HDAC6 in cell-lines may not apply to neurons.  
HDAC6-knockout R6/2 mice showed neither symptomatic improvement, nor 
changes in mHtt aggregate load (Bobrowska et al., 2011). Studies reporting increased mHtt 
clearance upon induction of autophagy have most frequently used 68-97Q mHtt (Ravikumar 
et al., 2004; Jeong et al., 2009; Rose et al., 2010; Tsvetkov et al., 2010; Jia et al., 2012), 
whereas HDAC6-knockout R6/2 had an unusually high mHtt polyQ – 201Q (Bobrowska et 
al., 2011). Aggregates precede symptom onset in R6/2 (Bobrowska et al., 2011), and data 
from neuronal models predict that diminishing diffuse mHtt levels should be more beneficial 
in the ‘pre-aggregate epoch’ (Miller et al., 2010). Although HDAC6-knockout R6/2 showed 
no changes in global levels of soluble mHtt, their cortex showed decreased soluble mHtt 
(no data on soluble mHtt was reported for their striatum; Bobrowska et al., 2011). Therefore, 
it would be valuable to start HDAC6 inhibition at the pre-aggregate epoch and test for 
delayed symptom onset in HD mice with shorter polyQ and slower disease progression. 
 
Concluding remarks 
The intrinsic balance towards fission and lower motility of striatal mitochondria may 
contribute towards the greater sensitivity of striatal neurons to HD-associated mitochondrial 
fragmentation and impaired trafficking. Pharmacological HDAC6 inhibition with TBA 
approximates the mitochondrial fission-fusion balance and motility of striatal neurons to that 
of the less HD-vulnerable cortical neurons, and also increases neuronal autophagic flux, 
promoting clearance of diffuse mHtt in striatal neurons. Recent in vivo studies support 
HDAC6 inhibition as a neuroprotective strategy in Alzheimer’s disease (Govindarajan et al., 
2013), Charcot-Marie-Tooth (d'Ydewalle et al., 2011), and amyothrophic lateral sclerosis 
(Taes et al., 2013). The present study supports pharmacological HDAC6 inhibition as a 
strategy with the potential to reduce striatal vulnerability to HD.
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As reviewed in Guedes-Dias and Oliveira (2013), although the association between 
HDAC6 inhibition and increased mitochondrial trafficking in neurons was well documented, 
the effects of HDAC activity modulation on mitochondrial biogenesis and fission-fusion 
balance in neurons were still largely unexplored. Moreover, it remained an open question 
whether the use of HDAC6 inhibitors to enhance mitochondrial motility, particularly in 
Huntington’s disease (HD), could compromise autophagic clearance and mutant huntingtin 
(mHtt) degradation. We addressed these points in Guedes-Dias et al. (2015) and our 
findings showed that: 1) neither exposure to MS-275, an HDAC1 inhibitor, nor to Tubastatin 
A (TBA), an HDAC6 inhibitor, modified mitochondrial biogenesis in neurons; 2) HDAC1 
inhibition reduced mitochondrial fission by decreasing Fis1 expression levels, whereas 
HDAC6 inhibition increased mitochondrial motility, inducing mitochondrial fusion in striatal 
neurons; 3) HDAC6 inhibition did not block autophagosome-lysosome fusion in neurons; 4) 
HDAC6 inhibition increased neuronal autophagic flux; 5) HDAC6 inhibition reduced levels 
of diffuse mHtt in striatal neurons. 
The therapeutic potential of neuronal HDAC1 inhibition is still controversial. HDAC1 
depletion reduced mHtt acetylation and promoted mHtt clearance, which could prove 
effective in HD (Jeong et al., 2009), and HDAC1 inhibition in dorsal root ganglion neurons 
was reported to facilitate central axon regeneration after peripheral axotomy, which could 
be potentially useful in treating spinal cord injuries (Finelli et al., 2013). However, HDAC1 
inhibition is also associated with inducing aberrant expression of cell-cycle genes, DNA 
damage and neuronal death both in vitro and in vivo (Kim et al., 2008). Our results show 
that HDAC1 inhibition blocked neurite outgrowth in cortical and striatal neurons, without 
altering mitochondrial biogenesis. One possible explanation is that, since HDAC1 inhibition 
decreased the expression of mitochondrial fission protein Fis1, reduced mitochondrial 
fission hindered the distribution of mitochondria to growing neurites, thus impairing their 
outgrowth (Ishihara et al., 2009).  
HDAC6 inhibition promoted neurite outgrowth in developing cortical neurons, which is in 
line with a previous study (Rivieccio et al., 2009). Although HDAC6 inhibition did not alter 
mitochondrial biogenesis, increased tubulin acetylation may have promoted mitochondrial 
distribution to the neuritic arbor, facilitating energy supply to growth cones. Indeed, we 
detected increased mitochondrial motility in mature neurons after HDAC6 inhibition – an 
effect that could be especially beneficial for striatal neurons, given the lower motility of their 
mitochondrial population compared to the less HD-vulnerable cortical neurons.  
In this thesis, we show that cortical and striatal neurons present differential 
mitochondrial dynamics and argue that this may be a contributing factor for striatal neurons 
preferential vulnerability in HD. Increased mitochondrial fragmentation (Shirendeb et al.,
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2011; Song et al., 2011; Shirendeb et al., 2012), decreased levels of acetylated -tubulin in 
patient brains (Dompierre et al., 2007), and impaired mitochondrial trafficking in striatal 
neurons (Orr et al., 2008) are associated with HD. Our findings show that mitochondria are 
less motile in striatal than cortical neurons, suggesting that this may underlie the higher 
susceptibility of striatal (Orr et al., 2008) over cortical neurons (Chang et al., 2006) to 
mitochondrial trafficking impairment by diffuse mHtt. Mitochondrial fraction per neurite 
length was similar between cortical and striatal neurons, importantly, however, mitochondria 
in striatal neurons were smaller and more numerous, suggesting that their dynamics are 
inherently balanced towards fission. Moreover, the higher expression levels of Fis1 detected 
in striatal neurons may predispose mitochondria to further fragmentation by overactivated 
Drp1 in HD (Song et al., 2011). HDAC6 inhibition increased -tubulin acetylation, promoting 
mitochondrial motility and fusion in striatal neurons to levels similar to those observed in 
less HD-vulnerable cortical neurons. This suggests that inhibiting HDAC6 may counteract 
the HD-associated mitochondrial fragmentation and trafficking impairment in striatal 
neurons. Future studies, however, should investigate whether HDAC6 inhibition rescues 
mitochondrial dynamics in striatal neurons expressing mHtt. 
HDAC6 inhibition did not block neuronal autophagosome-lysosome fusion or mHtt 
clearance, but in fact, induced autophagic flux and decreased diffuse mHtt levels in striatal 
neurons. Interestingly, our results suggest that HDAC6 inhibition induced autophagic flux 
not by boosting LC3-vesicles retrograde velocity, but instead by evoking autophagosomal 
biogenesis. Evidence indicates that mHtt proteostasis is, at least in part, mediated by 
autophagy: a small-molecule autophagy inducer decreased diffuse mHtt levels in neurons 
(Tsvetkov et al., 2010), whereas low concentrations of an autophagy inhibitor elevated 
diffuse mHtt lifetime (Tsvetkov et al., 2013). We therefore hypothesize that autophagy 
induction by HDAC6 inhibition may account for the diffuse mHtt levels decrease we 
observed in striatal neurons. Nevertheless, future studies are required to elucidate the 
mechanisms by which HDAC6 inhibition may promote autophagosomal biogenesis. 
Moreover, since we assessed autophagic flux in wild-type striatal neurons, further studies 
are needed to confirm whether HDAC6 inhibition increases LC3-vesicle flux towards the 
soma of striatal neurons expressing mHtt. Finally, performing a longitudinal analysis in 
individual mHtt-expressing striatal neurons to assess whether HDAC6 inhibition decreases 
their risk of death, will be critical to confirm the potential of HDAC6 inhibition to reduce 
striatal vulnerability in HD. 
Altered mitochondrial dynamics and defective autophagy are involved in HD 
pathology. Correcting mitochondrial shape and trafficking defects (Costa and Scorrano, 
2012), and stimulating autophagy clearance (Martin et al., 2015) are thus regarded as
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potentially beneficial in HD. Here, we show that HDAC6 inhibition promotes mitochondrial 
motility and induces mitochondrial fusion in HD-vulnerable striatal neurons to levels similar 
to those found in the less HD-vulnerable cortical neurons. Moreover, we show that HDAC6 
pharmacological inhibition does not inhibit neuronal autophagosome-lysosome fusion, but 
in fact, promotes autophagic flux and reduces the levels of diffuse mHtt in striatal neurons. 
In conclusion, our findings here support HDAC6 inhibition as a promising strategy to reduce 
the vulnerability of striatal neurons in HD.   
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